Bio Techne Corporation (TECH)

Merck KGaA, Darmstadt, Germany, Agrees to Acquire Bio-Techne, Strengthening Leadership Position in Fast-Growing Life Sciences MarketsJune 25, 2026 6:10 AM
PR Newswire (US) Purchase price of US$73 per share in cash represents an enterprise value of US$11.3 billion (EUR 9.9 billion)Proposed acquisition expected to be immediately accretive to sales growth and EBITDA pre margin post-closing, and EPS pre accretive by year 3 after closingU.S.-based Bio-Techne to bring portfolio with industry-leading multi-omics offering, analytical technologies and integrated workflow solutions across the scientific journeyWould deliver on growth agenda of Merck KGaA, Darmstadt, Germany, by expanding presence in high-growth, next-generation life sciences markets and further strengthening the position as a leader along the full life science value chainWould add complementary strengths across research, bioprocessing and advanced therapeutics, bolstering the offering of Merck KGaA, Darmstadt, Germany, in next-generation biologySynergistic platform would broaden offerings, accelerate innovation pipeline of Merck KGaA, Darmstadt, Germany, and increase Bio-Techne's geographic and omnichannel access for customers Merck KGaA, Darmstadt, Germany, expects annual cost synergies of approximately EUR 140 million, which are anticipated to be fully realized by year 3 after closingDARMSTADT, Germany and MINNEAPOLIS, June 25, 2026 /PRNewswire/ -- Merck KGaA, Darmstadt, Germany, a leading science and technology company, and Bio-Techne Corporation (NASDAQ: TECH), a Minneapolis-based global provider of life science tools, analytical technologies, and consumables, today entered into a definitive agreement pursuant to which Merck KGaA, Darmstadt, Germany, will, subject to customary closing conditions, acquire Bio-Techne for US$73 per share in cash, representing a total enterprise value of approximately US$11.3 billion (EUR 9.9 billion), a 36% premium to Bio-Techne's one-month volume weighted average trading price.The transaction would bring together two highly complementary and leading life sciences organizations, uniquely positioned to support customers across the full spectrum of life science workflows – from discovery and translational research through development, testing and commercial manufacturing. Additionally, it would directly deliver on the mid- to long-term strategic agenda of Merck KGaA, Darmstadt, Germany, which focuses on high-growth value drivers, integrated workflows, platformed capabilities and scaling and sourcing innovation through M&A."This transaction is an important milestone towards delivering on our mid- to long-term strategic agenda. Bio-Techne is an outstanding fit that directly supports our strategic direction focused on delivering cutting-edge products and solutions across the entire industry value chain – from lab customers to those manufacturing in the biotech and pharmaceutical industries," said Kai Beckmann, Chairman of the Executive Board and Group CEO of Merck KGaA, Darmstadt, Germany. "By combining Bio-Techne's scientific depth, innovation engine and differentiated portfolio with the global scale, manufacturing excellence and customer reach of Merck KGaA, Darmstadt, Germany, we are in a strong position to address some of the most important opportunities in life sciences and support our customers in accelerating the next generation of scientific discovery and therapeutic innovation. This positions us to deliver compelling strategic and financial benefits for shareholders, customers and employees.""Building on our strong track record in the Life Science Business, this transaction strengthens our presence in some of the most exciting and fastest-growing areas of the life sciences, including multi-omics, spatial biology, precision diagnostics and cell and gene therapy," said Jean-Charles Wirth, Member of the Executive Board of Merck KGaA, Darmstadt, Germany, and CEO Life Science. "It adds capabilities across our Discovery Solutions, Advanced Solutions and Process Solutions offerings, to support customers across increasingly complex scientific workflows.""For 50 years, Bio-Techne has enabled scientific breakthroughs across proteomics, spatial biology, and novel therapeutics," said Kim Kelderman, President and Chief Executive Officer of Bio-Techne. "This transaction is a testament to the remarkable company our team has built and to the enduring value we create for our customers and stakeholders. As part of Merck KGaA, Darmstadt, Germany, we will have greater scale and expanded capabilities to accelerate innovation and deepen our impact. Together, we will empower our customers to tackle the most important challenges in science and healthcare, helping to improve outcomes worldwide.""Following a thorough review, Bio-Techne's Board of Directors determined that this transaction represents an excellent opportunity for Bio-Techne and delivers substantial, near-term cash value to shareholders," said Robert V. Baumgartner, Chairman of the Board of Directors of Bio-Techne. "We are confident that, as part of Merck KGaA, Darmstadt, Germany, Bio-Techne will be well positioned to leverage its strong foundation and expand its impact across life sciences."Adding Differentiated Technologies Across the Life Science Value Chain 
Bio-Techne is a leader in recombinant proteins with 50 years of heritage in next-generation research and development and new modalities. Bio-Techne would bring to Merck KGaA, Darmstadt, Germany, a globally recognized portfolio of cytokines, growth factors, antibodies, and immunoassay kits.The planned acquisition would also add ProteinSimple, a leader in automated protein detection and analysis instruments, strengthening the analytical and bioprocess solutions of Merck KGaA, Darmstadt, Germany. In addition, Bio-Techne's RNAscope and related in situ hybridization technologies would strengthen the capabilities of Merck KGaA, Darmstadt, Germany, in spatial biology and diagnostics.Merck KGaA, Darmstadt, Germany, would also benefit from Bio-Techne's position as a leading provider of materials, analytics, and process technologies to cell therapy developers. In fiscal year 2023, Bio-Techne acquired 19.9% of Wilson Wolf Corporation ("Wilson Wolf"), a leading manufacturer of cell culture devices, including the G-Rex product line, and Bio-Techne expects to acquire the remaining ownership in Wilson Wolf immediately following the end of calendar year 2027 under the terms of a two-part forward contract between Wilson Wolf and Bio-Techne.Bio-Techne is headquartered in Minneapolis, Minnesota and has more than 3,000 employees, with approximately 2,300 employees based in the U.S. It operates 34 global locations and 15 manufacturing facilities across the U.S., Canada, the UK, Switzerland and China and generated net sales of more than US$1.2 billion in fiscal year 2025.Strengthening the Leading Life Science Capabilities and Global Reach of Merck KGaA, Darmstadt, Germany
The planned acquisition would strengthen the position of Merck KGaA, Darmstadt, Germany, in high-growth and accelerating areas, including multi-omics, spatial biology, cell and gene therapy, precision diagnostics and advanced research tools, while providing Bio-Techne with access to new channels and customer touchpoints as well as the global scale, manufacturing expertise and established Life Science infrastructure of Merck KGaA, Darmstadt, Germany.It would also bolster and broaden the Process Solutions business unit of Merck KGaA, Darmstadt, Germany, by expanding its reach into higher-value reagents, analytics, and cell and gene therapy workflows, and strengthen discovery, development and manufacturing capabilities.Together, Merck KGaA, Darmstadt, Germany, and Bio-Techne would bring enhanced scientific depth and the technical capabilities needed to support increasingly complex customer needs across next-generation biology workflows.Organizational Opportunities
Merck KGaA, Darmstadt, Germany, has a strong global footprint and track record as a leading employer. Over the past two decades, the company has invested more than US$35 billion (EUR 30 billion) through inorganic growth, including in the U.S. with acquisitions such as Millipore in 2010, Sigma-Aldrich in 2015, Versum in 2019, and, most recently, SpringWorks Therapeutics in 2025. Today, Merck KGaA, Darmstadt, Germany, employs more than 14,000 people in the U.S. across over 70 company and customer sites.The planned combination would unite teams across North America, Europe, Asia-Pacific and other key markets, creating a more connected global organization with enhanced opportunities for collaboration, mobility and professional growth. Merck KGaA, Darmstadt, Germany, intends to leverage the unique strengths and expertise of both organizations while continuing to invest in the capabilities, development and long-term success of its workforce worldwide.As part of a larger global Life Science organization, Bio-Techne employees would have opportunities to contribute to a broader range of innovation, customer and growth priorities, while benefiting from greater access to international networks, advanced training and participation in larger-scale innovation programs. Together, these opportunities are expected to strengthen the company's ability to attract, retain and develop top talent globally, supporting continued scientific leadership and sustainable growth.Financing & Transaction Details
Under the terms of the merger agreement, Bio-Techne shareholders will receive US$73 per share in cash, representing a total enterprise value of approximately US$11.3 billion (EUR 9.9 billion). The proposed transaction has been approved by Bio-Techne's Board of Directors and the relevant corporate bodies of Merck KGaA, Darmstadt, Germany, and is expected to close by late 2026 or early 2027, subject to satisfaction of customary closing conditions, including receipt of required regulatory approvals and approval by Bio-Techne shareholders.The planned acquisition will be funded through a combination of existing cash on hand and proceeds from new debt. Merck KGaA, Darmstadt, Germany, will preserve a strong investment-grade credit rating.Financial Benefits & Disciplined Execution
The proposed transaction is expected to be immediately accretive to EBITDA pre margin of both Life Science and the Group post-closing and EPS pre accretive by year 3 after closing. Cost synergies of approximately EUR 140 million are expected to be fully realized by year 3 after closing.Merck KGaA, Darmstadt, Germany, has a strong track record of successfully integrating acquisitions, including larger-scale and capability-expanding transactions, while delivering strategic, operational and financial value creation. Building on this experience, the company is committed to executing a thoughtful integration process focused on business continuity, critical talent retention, scientific capabilities and customer relationships. Value creation is expected to come from stronger growth, broader capabilities, improved customer reach and disciplined integration.Advisors 
Guggenheim Securities and J.P. Morgan are acting as financial advisors to Merck KGaA, Darmstadt, Germany, and Sullivan & Cromwell LLP is acting as the legal counsel of Merck KGaA, Darmstadt, Germany. Goldman Sachs & Co. LLC is acting as exclusive financial advisor to Bio-Techne, and Sidley Austin LLP is acting as Bio-Techne's legal counsel.Media & Investor Calls
Merck KGaA, Darmstadt, Germany, will host a media call today at 12:00 p.m. CEST, and a conference call with the financial community today at 2:00 p.m. CEST.About Merck KGaA, Darmstadt, Germany
Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates across life science, healthcare and electronics. More than 62,000 employees work to make a positive difference to millions of people's lives every day by creating more joyful and sustainable ways to live. From providing products and services that accelerate drug development and manufacturing as well as discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2025, Merck KGaA, Darmstadt, Germany, generated sales of € 21.1 billion in 65 countries.The company holds the global rights to the name and trademark "Merck" internationally. The only exceptions are the United States and Canada, where the business sectors of Merck KGaA, Darmstadt, Germany, operate as MilliporeSigma in life science, EMD Serono in healthcare and EMD Electronics in electronics. Since its founding in 1668, scientific exploration and responsible entrepreneurship have been key to the company's technological and scientific advances. To this day, the founding family remains the majority owner of the publicly listed company.All Merck KGaA, Darmstadt, Germany, press releases are distributed by e-mail at the same time they become available on the EMD Group website. In case you are a resident of the USA or Canada, please go to www.emdgroup.com/subscribe to register for your online, change your selection or discontinue this service.About Bio-Techne
Bio Techne Corporation (NASDAQ: TECH) is a global life sciences company headquartered in Minnesota, celebrating 50 years of empowering scientific and diagnostic communities to reach better answers. The company provides high quality reagents, analytical instruments, and precision diagnostics. Its portfolio is organized into three customer focused brands: R&D Systems™, Bio Techne Spatial™, and Bio Techne Diagnostics™, reflecting the scientific journey from discovery to translational research to clinical decision making. Bio Techne operates in 34 locations worldwide and employs more than 3,000 people. In fiscal year 2025, the company generated over $1.2 billion in net sales. Its more than 500,000 products are used globally by academic researchers, biopharmaceutical and biotechnology companies, and clinical diagnostic laboratories.For more information on Bio-Techne, please visit www.bio-techne.com or follow the company on LinkedIn, X, or YouTube.Bio-Techne Contacts
David Clair, Vice President Investor Relations
IR@bio-techne.comMedia contacts:
Corporate Communications
media.relations@bio-techne.comJoele Frank, Wilkinson Brimmer Katcher
Kelly Sullivan / Jamie Moser
+1 212-355-4449Cautionary Statement Regarding Forward-Looking Statements
This communication may contain forward-looking statements based on current assumptions and forecasts made by Merck KGaA, Darmstadt, Germany or Bio-Techne Corporation ("Bio-Techne") management. Statements that include words such as "anticipate," "expect," "should," "would," "intend," "plan," "project," "seek," "believe," "will," and other words of similar meaning in connection with future events or future operating or financial performance are often used to identify forward-looking statements. All statements in this communication, other than those relating to historical information or current conditions, are forward-looking statements. Actual results could differ materially from those projected or forecasted in the forward-looking statements. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation or development and the estimates given here. These factors include the following: Merck KGaA, Darmstadt, Germany's ability to successfully complete the proposed acquisition of Bio-Techne or realize the anticipated benefits of the proposed transaction in the expected timeframes or at all; Merck KGaA, Darmstadt, Germany's ability to successfully integrate Bio-Techne's operations into those of Merck KGaA, Darmstadt, Germany, given such integration may be more difficult, time-consuming or costly than expected; the failure to obtain Bio-Techne's shareholders' approval of the proposed transaction; the failure of any of the conditions to the proposed transaction to be satisfied; the possibility that competing offers or acquisition proposals for Bio-Techne will be made; revenues following the proposed transaction may be lower than expected; operating costs, customer loss and business disruption (including, without limitation, difficulties in maintaining relationships with employees, customers, clients or suppliers) may be greater than expected following the proposed transaction; the retention of certain key employees at Bio-Techne; risks associated with the disruption of management's attention from ongoing business operations due to the proposed transaction; certain restrictions during the pendency of the proposed transaction that may impact Bio-Techne's or Merck KGaA, Darmstadt, Germany's ability to pursue certain business opportunities or strategic transactions; the risk that any announcements relating to the proposed transaction could have adverse effects on the market price of Bio-Techne's common stock, including if the proposed transaction is not consummated; the outcome of any legal proceedings related to the proposed transaction; the impact of the proposed transaction on Bio-Techne's credit rating; the parties' ability to meet expectations regarding the timing and completion of the proposed transaction; delays in obtaining any approvals required to complete the proposed transaction or an inability to obtain them on the terms proposed or on the anticipated schedule or regarding accounting and tax treatments of the proposed transaction; the impact of indebtedness to be incurred by Merck KGaA, Darmstadt, Germany in connection with the proposed transaction; the effects of the business combination of Bio-Techne and Merck KGaA, Darmstadt, Germany, including the combined company's future financial condition, operating results, strategy and plans; third parties may claim that Merck KGaA, Darmstadt, Germany's or Bio-Techne's products infringe their intellectual property rights; fluctuations in non-U.S. currencies could result in transaction losses; acts of war and terrorism may adversely affect Merck KGaA, Darmstadt, Germany's or Bio-Techne's business; the volatility of the international marketplace; and other factors discussed in Merck KGaA, Darmstadt, Germany's public reports which are available on Merck KGaA, Darmstadt, Germany's website at https://www.emdgroup.com/en or in Bio-Techne's Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (the "SEC") for the fiscal year ended June 30, 2025 and Bio-Techne's other filings with the SEC, which are available at http://www.sec.gov and on Bio-Techne's website at https://www.bio-techne.com. Except as otherwise required by law, neither Merck KGaA, Darmstadt, Germany nor Bio-Techne assumes any liability whatsoever to update these forward-looking statements or to conform them to future events or developments. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof.Additional Important Information and Where to Find It
This communication relates to the proposed transaction involving Bio-Techne and Merck KGaA, Darmstadt, Germany. In connection with the proposed transaction, Bio-Techne intends to file relevant materials with the SEC, including a proxy statement on Schedule 14A (the "Proxy Statement"). This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval, and is not a substitute for the Proxy Statement or any other document that Bio-Techne files with the SEC or sends to Bio-Techne's shareholders in connection with the proposed transaction. SHAREHOLDERS OF BIO-TECHNE ARE URGED TO READ ALL RELEVANT DOCUMENTS FILED WITH THE SEC, INCLUDING ALL PROXY MATERIALS, WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION. Investors and security holders will be able to obtain the documents (when available) free of charge at the SEC's website, http://www.sec.gov, or on Bio-Techne's website at https://www.bio-techne.com.Participants in Solicitation
Bio-Techne and its directors and executive officers, and Merck KGaA, Darmstadt, Germany and certain of its executive officers, may be deemed to be participants in the solicitation of proxies from the holders of Bio-Techne common stock in respect of the proposed transaction. Information about the directors and executive officers of Bio-Techne is set forth (i) in Bio-Techne's proxy statement for its 2025 annual meeting of shareholders, which was filed with the SEC on September 19, 2025, which is available here, including under the headings "Proposal 2: Election of Directors," "Corporate Governance," "Director Compensation," "Executive Compensation" and "Share Information", and (ii) under Item 5.02, "Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers" in the Current Report on Form 8-K filed by Bio-Techne with the SEC on February 11, 2026 (which is available here). To the extent holdings of Bio-Techne's securities by its directors or executive officers have changed since the amounts set forth in such documents, such changes have been or will be reflected on Initial Statements of Beneficial Ownership on Form 3 or Statements of Beneficial Ownership on Form 4 filed with the SEC that are or will be available at the SEC's website, http://www.sec.gov. Other information regarding the participants in the proxy solicitation and a description of their direct and indirect interests, by security holdings or otherwise, will be contained in the Proxy Statement and other relevant materials to be filed with the SEC in respect of the proposed transaction when they become available.Media Relations
media@emdgroup.com
Phone: +49 151 1454 9258Investor Relations
investor.relations@emdgroup.com
Phone: +49 6151 72 3321 View original content to download multimedia:https://www.prnewswire.com/news-releases/merck-kgaa-darmstadt-germany-agrees-to-acquire-bio-techne-strengthening-leadership-position-in-fast-growing-life-sciences-markets-302810602.htmlSOURCE Bio-Techne Corporation Original: Merck KGaA, Darmstadt, Germany, Agrees to Acquire Bio-Techne, Strengthening Leadership Position in Fast-Growing Life Sciences Markets

Bio-Techne and Refeyn Close Critical Gap in Bispecific Antibody and Biosimilar CharacterizationJune 4, 2026 6:30 AM
PR Newswire (US) New integrated workflow combines icIEF fractionation and mass photometryEnables direct characterization of aggregation and size within icIEF-resolved charge variantsFour-hour workflow reduces development risk and accelerates biosimilar manufacturingMINNEAPOLIS and OXFORD, England, June 4, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a global provider of life science tools, reagents and diagnostic products, and Refeyn, the pioneer in mass photometry technology, today announced a first-of-its-kind integrated workflow for the characterization of charge and size variants in bispecific antibodies and biosimilars.By combining R&D Systems MauriceFlex™ imaged capillary isoelectric focusing (icIEF) fractionation system with Refeyn's TwoMP mass photometry platform, researchers can directly correlate charge heterogeneity with molecular weight and aggregation at single-molecule resolution in a streamlined four-hour workflow.Bispecific antibodies are among the fastest-growing classes of biotherapeutics, but their structural complexity makes thorough characterization challenging. Incomplete characterization can delay development, increase manufacturing risk, and lead to costly late-stage failures.The MauriceFlex™ system delivers high-resolution separation and fractionation of charge variants, a capability increasingly expected in regulatory submissions. However, analyzing the size and aggregation of individual charge fractions has historically been difficult due to the large sample requirements of traditional methods.The integrated workflow addresses this challenge directly by pairing icIEF fractionation with mass photometry. Charge variants are first separated using MauriceFlex™, then analyzed on Refeyn's TwoMP platform, which requires only nanogram-level sample and reveals size distribution and aggregation at single-molecule resolution.Together, the technologies enable direct characterization of aggregation and size within icIEF-resolved charge variants—an insight not accessible with standalone methods—reducing reliance on multiple tests and enabling faster, more efficient process development."Bispecifics are the fastest growing segment within next-generation antibodies, but they are very difficult to characterize. This approach directly addresses one of the biggest challenges by combining icIEF fractionation with mass photometry. Researchers can now interrogate charge and size variants together in a single workflow," said Gerry Mackay, CEO of Refeyn."Our customers are under intense pressure to develop and manufacture increasingly complex biologics faster and more efficiently. Enabling deeper characterization with less sample helps them reduce risk, control costs, and make better decisions earlier in development," said Will Geist, President Bio-Techne Protein Sciences Segment.In a joint webinar, scientists demonstrated the workflow using Mosunetuzumab-axgb and a biosimilar, tracking size-related changes in the molecule across charge variant fractions under multiple conditions. An application note with full findings is available here.The workflow will also be presented at the American Society for Mass Spectrometry (ASMS) conference, taking place May 31 – June 4, 2026, in San Diego. See booth and poster details hereABOUT BIO-TECHNEBio-Techne Corporation (NASDAQ: TECH) is a global life sciences company headquartered in Minnesota, celebrating 50 years of empowering scientific and diagnostic communities to reach better answers. The company provides high-quality reagents, analytical instruments, and precision diagnostics. Its portfolio is organized into three customer-focused brands: R&D Systems™, Bio-Techne Spatial™, and Bio-Techne Diagnostics™, reflecting the scientific journey from discovery to translational research to clinical decision making. Bio-Techne operates in 34 locations worldwide and employs approximately 3,000 people. In fiscal year 2025, the company generated over $1.2 billion in net sales. Its more than 500,000 products are used globally by academic researchers, biopharmaceutical and biotechnology companies, and clinical diagnostic laboratories.For more information on Bio-Techne, please visit www.bio-techne.com or follow the company on LinkedIn, X, or YouTube.ABOUT REFEYNRefeyn specializes in the development, production, and distribution of mass photometry solutions for industry and academia. Its innovative technology enables accurate mass measurement of single molecules in their native state without labels, delivering faster insights with minimal sample compared to conventional methods.For more information on Refeyn, please visit www.refeyn.com or follow the company on LinkedIn or YouTube.MEDIA CONTACTS:Bio-Techne
David Clair, Vice President Investor Relations
IR@bio-techne.com Corporate Communications
media.relations@bio-techne.com Refeyn
Catie Lichten
Scientific Communications Manager
catie.lichten@refeyn.com   View original content to download multimedia:https://www.prnewswire.com/news-releases/biotechne-and-refeyn-close-critical-gap-in-bispecific-antibody-and-biosimilar-characterization-302791071.htmlSOURCE Bio-Techne Corporation Original: Bio-Techne and Refeyn Close Critical Gap in Bispecific Antibody and Biosimilar Characterization

Bio-Techne Declares DividendMay 6, 2026 6:30 AM
PR Newswire (US) MINNEAPOLIS, May 6, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended March 31, 2026. The quarterly dividend will be payable May 29, 2026, to all common shareholders of record on May 18, 2026. Future cash dividends will be considered by the Board of Directors on a quarterly basis.Bio–Techne Corporation (NASDAQ: TECH) is a global life sciences company headquartered in Minnesota, celebrating 50 years of empowering scientific and diagnostic communities to reach better answers. The company provides high–quality reagents, analytical instruments, and precision diagnostics. Its portfolio is organized into three customer–focused brands: R&D Systems™, Bio–Techne Spatial™, and Bio–Techne Diagnostics™, reflecting the scientific journey from discovery to translational research to clinical decision–making. Bio–Techne operates in 34 locations worldwide and employs approximately 3,100 people. In fiscal year 2025, the company generated over $1.2 billion in net sales. Its more than 500,000 products are used globally by academic researchers, biopharmaceutical and biotechnology companies, and clinical diagnostic laboratories. For more information on Bio-Techne and its brands, please visit www.bio-techne.com or follow the company on social media at LinkedIn, X, or YouTube. Forward Looking Statements:
Our press releases may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Such statements involve risks and uncertainties that may affect the actual results of operations. Forward looking statements in this press release include statements regarding potential future repurchase of Bio-Techne common stock. The following important factors, among others, have affected and, in the future, could affect the Company's actual results and future share price: the effect of new branding and marketing initiatives, the integration of new businesses and leadership, the introduction and acceptance of new products, the funding and focus of the types of research by the Company's customers, the impact of the growing number of producers of biotechnology research products and related price competition, general economic conditions, customer site closures or supply chain issues, the impact of currency exchange rate fluctuations, and the costs and results of research and product development efforts of the Company and of companies in which the Company has invested or with which it has formed strategic relationships.For additional information concerning such factors, see the section titled "Risk Factors" in the Company's annual report on Form 10-K and quarterly reports on Form 10-Q as filed with the Securities and Exchange Commission. We undertake no obligation to update or revise any forward-looking statements we make in our press releases due to new information or future events. Investors are cautioned not to place undue emphasis on these statements.Contact: David Clair, Vice President, Investor Relations
David.Clair@bio-techne.com
612-656-4416 View original content to download multimedia:https://www.prnewswire.com/news-releases/bio-techne-declares-dividend-302763478.htmlSOURCE Bio-Techne Corporation Original: Bio-Techne Declares Dividend

Bio-Techne Releases Third Quarter Fiscal 2026 ResultsMay 6, 2026 6:30 AM
PR Newswire (US) MINNEAPOLIS, May 6, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today reported its financial results for the third quarter ending March 31, 2026.Third Quarter FY2026 HighlightsReported and organic revenue declined 2% to $311.4M, negatively impacted by prior-year GMP fast-track orders and timing of large Commercial Supply shipmentsGAAP EPS increased to $0.32 from $0.14; adjusted EPS was $0.53, down from $0.56Large pharma delivered the sixth consecutive quarter of double-digit growth, offset by a continued lag in spending by emerging biotech; U.S. academic markets stabilized with low-single-digit growthGrowth vectors performed well, with mid-single-digit growth in Proteomic Analysis instruments, mid-teens growth in Spatial Biology, and nearly 50% growth in GMP proteins excluding fast-track customers"The Bio-Techne team delivered solid execution amid a mixed end-market environment," said Kim Kelderman, President and Chief Executive Officer of Bio-Techne. "Large pharma again led results with the sixth consecutive quarter of double-digit growth, supported by momentum in Asia and stabilizing U.S. academic demand. While biotech funding remains healthy, it has not yet translated into broad-based demand across our portfolio."Kelderman continued, "We are encouraged by early indicators pointing to a more constructive outlook as funding activity and customer purchasing begin to realign. Our portfolio is organized to support durable, high-value applications across the scientific journey, from biological discovery and translational insight to therapeutic development, manufacturing, and precision diagnostics. Together with our strong operating discipline and financial flexibility, Bio-Techne remains well positioned to deliver attractive long-term value for our stakeholders."Conference CallBio-Techne will host an earnings conference call today, May 6, 2026, at 8:00 a.m. CDT. To listen, please dial 1-800-343-4136 or 1-203-518-9843 (for international callers), and reference conference ID TECHQ3. The earnings call can also be accessed via webcast through the following link https://investors.bio-techne.com/ir-calendar.A recorded rebroadcast will be available for interested parties unable to participate in the live conference call by dialing 1-844-512- 2921 or 1-412-317-6671 (for international callers) and referencing Conference ID 11161556. The replay will be available from 11:00 a.m. CDT on Wednesday, May 6, 2026, until 11:00 p.m. CDT on Saturday, June 6, 2026.Third Quarter Fiscal 2026RevenueNet sales for the third quarter decreased 2% to $311.4 million. Organic revenue decreased 2% compared to the prior year, with foreign currency exchange having a favorable impact of 2%, and non-recurring prior year revenue from a business held-for-sale having an unfavorable impact of 2%.GAAP Earnings ResultsGAAP EPS was $0.32 per diluted share versus $0.14 in the same quarter last year. GAAP operating income for the third quarter of fiscal 2026 increased 95% to $75.5 million compared to $38.7 million in the third quarter of fiscal 2025. GAAP operating margin was 24.2% compared to 12.2% in the third quarter of fiscal 2025. Current quarter GAAP operating margin was favorably impacted by ongoing profitability initiatives, the Exosome Diagnostics divestiture, and a non-recurring arbitration payment in the prior year, partially offset by unfavorable product mix.Non-GAAP Earnings ResultsAdjusted EPS decreased to $0.53 per diluted share compared to $0.56 in the same quarter last year. Adjusted operating income decreased to $106.5 million in the third quarter of fiscal 2026 compared to $110.3 million in the third quarter of fiscal 2025. Adjusted operating margin was 34.2% for the third quarter of fiscal 2026 compared to 34.9% in the third quarter of fiscal 2025. Adjusted operating margin was unfavorably impacted by volume and product mix, partially offset by ongoing profitability initiatives and the Exosome Diagnostics divestiture.Segment ResultsManagement uses adjusted operating results to monitor and evaluate performance of the Company's business segments, as highlighted below.Protein Sciences SegmentThe Company's Protein Sciences segment is one of the world's leading suppliers of specialized proteins such as cytokines and growth factors, immunoassays, antibodies and reagents, to the biopharma and academic research communities. Additionally, the segment provides an array of platforms essential in various areas of protein analysis. The Protein Sciences segment's third quarter fiscal 2026 net sales were $226.2 million, a decrease of 1% from $227.7 million in the third quarter of fiscal 2025. As of December 31, 2023, a business within the Protein Sciences segment met the criteria as held-for-sale; this held-for-sale business has been excluded from the segment's operating results for both periods presented. Organic revenue decreased 4% for the third quarter of fiscal 2026, with foreign currency exchange having a favorable impact of 3%. The Protein Sciences segment's operating margin decreased to 44.2% in the third quarter of fiscal 2026 compared to 45.6% in the third quarter of fiscal 2025. The segment's operating margin decreased primarily due to unfavorable volume and product mix, partially offset by ongoing profitability initiatives.Diagnostics and Spatial Biology SegmentThe Company's Diagnostics and Spatial Biology segment develops and provides spatial biology products, carrier screening and oncology kits. The Diagnostics and Spatial Biology segment also provides blood chemistry and blood gas quality controls, hematology instrument controls, immunoassays and other bulk and custom reagents for the in vitro diagnostic market. The Diagnostics and Spatial Biology segment's third quarter fiscal 2026 net sales were $85.6 million, a decrease of 4% from $89.2 million for the third quarter of fiscal 2025. As of June 30, 2025, a business within the Diagnostics and Spatial Biology segment met the criteria as held-for-sale; this held-for-sale business has been excluded from the segment's fiscal 2026 operating results. Organic revenue growth was 3% for the third quarter of fiscal 2026, with foreign exchange having a favorable impact of 1%. The held-for-sale business had an unfavorable impact of 8%. The Diagnostics and Spatial Biology segment's operating margin increased to 12.1% in the third quarter of fiscal 2026 compared to 9.4% in the third quarter of fiscal 2025. The segment's operating margin was favorably impacted by the Exosome Diagnostics divestiture and ongoing profitability initiatives, partially offset by unfavorable product mix.About Bio-TechneBio-Techne Corporation (NASDAQ: TECH) is a global life sciences company headquartered in Minnesota, celebrating 50 years of empowering scientific and diagnostic communities to reach better answers. The company provides high-quality reagents, analytical instruments, and precision diagnostics.  Its portfolio is organized into three customer-focused brands: R&D Systems™, Bio-Techne Spatial™, and Bio-Techne Diagnostics™, reflecting the scientific journey from discovery to translational research to clinical decision-making. Bio-Techne operates in 34 locations worldwide and employs approximately 3,100 people. In fiscal year 2025, the company generated over $1.2 billion in net sales.  Its more than 500,000 products are used globally by academic researchers, biopharmaceutical and biotechnology companies, and clinical diagnostic laboratories. For more information on Bio-Techne and its brands, please visit www.bio-techne.com or follow the company on social media at LinkedIn, X, or YouTube. Forward Looking Statements:This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act. These statements use words and variations of words, such as "will," "plan," "continue," "believe," "outlook," "expect," and "predict." These statements are made as of the date of this press release, are based on current expectations of future events, and thus are inherently subject to a number of risks and uncertainties, many of which involve factors or circumstances beyond the Company's control. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the Company's expectations and projections. These risks, uncertainties, and other factors include, without limitation: the effect of new branding and marketing initiatives, the integration of new businesses and leadership, the introduction and acceptance of new products, the funding and focus of the types of research by the Company's customers, the impact of the growing number of producers of biotechnology research products and related price competition, general economic conditions, the impact of currency exchange rate fluctuations, and the costs and results of research and product development efforts of the Company and of companies in which the Company has invested or with which it has formed strategic relationships.For additional information concerning these risks, uncertainties, and other factors, see the section titled "Risk Factors" in the Company's most recent annual report on Form 10-K as filed with the Securities and Exchange Commission. We undertake and we expressly disclaim any obligation to update or revise any forward-looking statements due to new information, changed assumptions, or future events, except as required by law. Investors are cautioned not to place undue reliance on forward-looking statements.Non-GAAP Financial Measures:The Company's financial statements are prepared in accordance with accounting principles generally accepted in the U.S. (GAAP). This press release contains financial measures that have not been calculated in accordance with GAAP. These non-GAAP measures include:Organic revenue and organic revenue growthAdjusted gross marginEarnings before interest, taxes, depreciation, and amortization (EBITDA)Adjusted EBITDAAdjusted operating incomeAdjusted operating marginAdjusted tax rateAdjusted net earningsAdjusted diluted earnings per shareThese non-GAAP measures should not be considered in isolation or as a substitute for any measure derived in accordance with GAAP and may also be inconsistent with similar measures presented by other companies. Reconciliations of these measures to the applicable most closely comparable GAAP measures, and reasons for the Company's use of these measures, are presented in the attached pages.Contact:David Clair, Vice President, Investor Relations
David.Clair@bio-techne.com
612-656-4416 BIO-TECHNE CORPORATIONCONDENSED CONSOLIDATED STATEMENTS OF EARNINGS(In thousands, except per share data)(Unaudited)














Quarter Ended
Nine Months Ended

March 31, 
March 31, 

2026
2025
2026
2025Net sales
$311,415
$316,181
$893,847
$902,671Cost of sales

103,127

101,625

306,170

311,211Gross margin

208,288

214,556

587,677

591,460Operating expenses:











Selling, general and administrative

109,338

151,269

339,242

391,881Research and development

23,455

24,579

70,821

73,464Total operating expenses

132,793

175,848

410,063

465,345Operating income

75,495

38,708

177,614

126,115Other income (expense)

(4,270)

(434)

(7,614)

(4,793)Earnings before income taxes

71,225

38,274

170,000

121,322Income taxes

20,178

15,686

42,759

30,244Net earnings
$51,047
$22,588
$127,241
$91,078Earnings per share:











Basic
$0.33
$0.14
$0.82
$0.58Diluted
$0.32
$0.14
$0.81
$0.57Weighted average common shares outstanding:











Basic

156,327

157,372

155,893

158,117Diluted

157,403

158,944

156,943

160,662 BIO-TECHNE CORPORATIONRECONCILIATION OF ADJUSTED GROSS MARGIN AND ADJUSTED GROSS MARGIN PERCENTAGE(In thousands)(Unaudited)















Quarter Ended
Nine Months Ended


March 31, 
March 31, 


2026
2025
2026
2025
Total consolidated net sales
$311,415
$316,181
$893,847
$902,671
Business held-for-sale(1)

—

—

5,439

4,152
Revenue from recurring operations
$311,415
$316,181
$888,408
$898,519














Gross margin - GAAP
$208,288
$214,556
$587,677
$591,460
Gross margin percentage - GAAP

66.9%
67.9%
65.7%
65.5%













Identified adjustments:












Costs recognized upon sale of acquired inventory
$—
$181
$—
$554
Amortization of intangibles

9,465

11,057

28,377

33,467
Stock-based compensation, inclusive of employer taxes

400

378

1,252

1,010
Restructuring and restructuring-related costs

1,152

364

4,756

7,953
Impact of business held-for-sale(1)

—

—

(2,581)

(147)
Adjusted gross margin
$219,305
$226,536
$619,481
$634,297
Adjusted gross margin percentage(2)

70.4%
71.6%
69.7%
70.6%















(1)March 31, 2025 amounts relate to the Protein Sciences segment business that met the held-for-sale criteria on December 31, 2023. March 31, 2026 amounts relate to the Diagnostics and Spatial Biology segment business that met the held-for-sale criteria on June 30, 2025.(2)Adjusted gross margin percentage excludes both revenue and gross margin of the businesses that met the held-for-sale criteria during the respective periods. BIO-TECHNE CORPORATIONRECONCILIATION OF GAAP NET INCOME TO ADJUSTED EBITDA(In thousands)(Unaudited)














Quarter Ended
Nine Months Ended

March 31, 
March 31, 

2026
2025
2026
2025Net earnings
$51,047
$22,588
$127,241
$91,078Net interest expense (income)

1,420

981

4,655

3,031Depreciation and amortization

24,169

27,571

73,218

82,792Income taxes

20,178

15,686

42,759

30,244EBITDA

96,814

66,826

247,873

207,145Amortization of Wilson Wolf intangible assets

2,490

2,491

7,469

7,471Acquisition related expenses and other

1,042

5,290

6,789

9,477Certain litigation charges

822

38,927

5,370

40,606Stock-based compensation, inclusive of employer taxes

10,968

11,629

37,262

37,504Restructuring and restructuring-related costs

2,952

716

14,201

15,027Investment (gain) loss and other non-operating (income) loss

1,618

—

1,314

—Recovery of assets held-for-sale

—

(3,655)

(6,789)

(3,655)Impact of business held-for-sale(1)

—

—

2,573

479Adjusted EBITDA
$116,706
$122,224
$316,062
$314,054

(1)March 31, 2025 amounts relate to the Protein Sciences segment business that met the held-for-sale criteria on December 31, 2023. March 31, 2026 amounts relate to the Diagnostics and Spatial Biology segment business that met the held-for-sale criteria on June 30, 2025. BIO-TECHNE CORPORATIONRECONCILIATION OF ADJUSTED OPERATING INCOME AND ADJUSTED OPERATING MARGIN PERCENTAGE(In thousands)(Unaudited)















Quarter Ended
Nine Months Ended


March 31, 
March 31, 


2026
2025
2026
2025
Total consolidated net sales
$311,415
$316,181
$893,847
$902,671
Business held-for-sale(1)

—

—

5,439

4,152
Revenue from recurring operations
$311,415
$316,181
$888,408
$898,519














Operating income - GAAP
$75,495
$38,708
$177,614
$126,115
Operating income percentage - GAAP

24.2%
12.2%
19.9%
14.0%













Identified adjustments:












Amortization of intangibles

15,382

18,836

46,111

57,136
Acquisition related expenses and other

897

5,159

6,341

9,051
Certain litigation charges

822

38,927

5,370

40,606
Stock-based compensation, inclusive of employer taxes

10,968

11,629

37,262

37,504
Restructuring and restructuring-related costs

2,952

716

14,201

15,027
Recovery of assets held-for-sale

—

(3,655)

(6,789)

(3,655)
Impact of business held-for-sale(1)

—

—

2,573

479
Adjusted operating income
$106,516
$110,320
$282,683
$282,263
Adjusted operating margin percentage(2)

34.2%
34.9%
31.8%
31.4%

(1)March 31, 2025 amounts relate to the Protein Sciences segment business that met the held-for-sale criteria on December 31, 2023. March 31, 2026 amounts relate to the Diagnostics and Spatial Biology segment business that met the held-for-sale criteria on June 30, 2025.(2)Adjusted operating margin percentage excludes both revenue and operating margin for the businesses that met the held-for-sale criteria during the respective periods. BIO-TECHNE CORPORATIONRECONCILIATION OF NON-GAAP ADJUSTED TAX RATE(In percentages)(Unaudited)














Quarter Ended
Nine Months Ended

March 31, 
March 31, 

2026
2025
2026
2025GAAP effective tax rate
28.3%
41.0%
25.2%
24.9%Discrete items
(0.5)

(19.5)

1.7

(1.8)
Annual forecast update
(0.9)

1.6

—

—
Long-term GAAP tax rate
26.9%
23.1%
26.9%
23.1%Rate impact items











Stock based compensation
(2.9)%
(1.0)%
(2.9)%
(3.8)%Other
(1.7)

(0.6)

(1.7)

2.2
Total rate impact items
(4.6)%
(1.6)%
(4.6)%
(1.6)%Non-GAAP adjusted tax rate
22.3%
21.5%
22.3%
21.5% BIO-TECHNE CORPORATIONRECONCILIATION OF ADJUSTED NET EARNINGS AND ADJUSTED EARNINGS PER SHARE(In thousands, except per share data)(Unaudited)
















Quarter Ended
Nine Months Ended

March 31, 
March 31, 

2026
2025

2026
2025
Net earnings before taxes - GAAP
$71,225
$38,274

$170,000
$121,322
Identified adjustments:













Amortization of intangibles

15,382

18,836


46,111

57,136
Amortization of Wilson Wolf intangible assets

2,490

2,491


7,469

7,471
Acquisition related expenses and other

1,042

5,290


6,789

9,477
Certain litigation charges

822

38,927


5,370

40,606
Stock-based compensation, inclusive of employer taxes

10,968

11,629


37,262

37,504
Restructuring and restructuring-related costs

2,952

716


14,201

15,027
Investment (gain) loss and other non-operating (income) loss

1,618

—


1,314

—
Recovery of assets held-for-sale

—

(3,655)


(6,789)

(3,655)
Impact of business held-for-sale(1)

—

—


2,573

479
Net earnings before taxes - Adjusted
$106,499
$112,508

$284,300
$285,367
Non-GAAP tax rate

22.3%
21.5%

22.3%
21.5%Non-GAAP tax expense
$23,749
$24,190

$63,399
$61,385
Non-GAAP adjusted net earnings
$82,750
$88,318

$220,901
$223,982
Earnings per share - diluted - Adjusted
$0.53
$0.56

$1.41
$1.39


(1)March 31, 2025 amounts relate to the Protein Sciences segment business that met the held-for-sale criteria on December 31, 2023. March 31, 2026 amounts relate to the Diagnostics and Spatial Biology segment business that met the held-for-sale criteria on June 30, 2025. BIO-TECHNE CORPORATIONSEGMENT REVENUE(In thousands)(Unaudited)














Quarter Ended
Nine Months Ended

March 31, 
March 31, 

2026
2025
2026
2025Protein Sciences segment revenue
$226,154
$227,687
$643,426
$643,774Diagnostics and Spatial Biology segment revenue

85,586

89,231

246,224

256,558Other revenue(1)

—

—

5,439

4,152lntersegment revenue

(325)

(737)

(1,242)

(1,813)Consolidated revenue
$311,415
$316,181
$893,847
$902,671

(1)March 31, 2025 amounts relate to the Protein Sciences segment business that met the held-for-sale criteria on December 31, 2023. March 31, 2026 amounts relate to the Diagnostics and Spatial Biology segment business that met the held-for-sale criteria on June 30, 2025. BIO-TECHNE CORPORATIONSEGMENT OPERATING INCOME(In thousands)(Unaudited)














Quarter Ended
Nine Months Ended

March 31, 
March 31,

2026
2025
2026
2025Protein Sciences segment operating income
$99,999
$103,910
$262,327
$271,564Diagnostics and Spatial Biology segment operating income

10,319

8,423

27,629

15,940Segment operating income

110,318

112,333

289,956

287,504Corporate general, selling, and administrative

(3,802)

(2,013)

(7,273)

(5,241)Adjusted operating income

106,516

110,320

282,683

282,263Amortization of intangibles

(15,382)

(18,836)

(46,111)

(57,136)Acquisition related expenses and other

(897)

(5,159)

(6,341)

(9,051)Certain litigation charges

(822)

(38,927)

(5,370)

(40,606)Stock-based compensation, inclusive of employer taxes

(10,968)

(11,629)

(37,262)

(37,504)Restructuring and restructuring-related costs

(2,952)

(716)

(14,201)

(15,027)Recovery of assets held-for-sale

—

3,655

6,789

3,655Impact of business held-for-sale(1)

—

—

(2,573)

(479)Operating income
$75,495
$38,708
$177,614
$126,115

(1)March 31, 2025 amounts relate to the Protein Sciences segment business that met the held-for-sale criteria on December 31, 2023. March 31, 2026 amounts relate to the Diagnostics and Spatial Biology segment business that met the held-for-sale criteria on June 30, 2025. BIO-TECHNE CORPORATIONCONDENSED CONSOLIDATED BALANCE SHEETS(In thousands)(Unaudited)








March 31,
June 30,

2026
2025ASSETS





Cash and equivalents
$209,819
$162,186Accounts receivable, net

214,562

206,876Inventories

201,175

189,446Current assets held-for-sale

—

12,332Other current assets

62,494

37,460Total current assets

688,050

608,300






Property and equipment, net

232,990

245,719Right of use assets

68,316

73,399Goodwill and intangible assets, net

1,296,874

1,346,534Other assets

264,371

283,916Total assets
$2,550,601
$2,557,868






LIABILITIES AND STOCKHOLDERS' EQUITY





Accounts payable and accrued expenses
$95,601
$116,765Contract liabilities

38,433

32,571Income taxes payable

2,971

10,770Operating lease liabilities - current

14,181

14,098Other current liabilities

2,092

1,645Total current liabilities

153,278

175,849






Deferred income taxes

14,210

6,169Long-term debt obligations

200,000

346,000Operating lease liabilities

76,141

83,960Other long-term liabilities

21,668

27,082Stockholders' equity

2,085,304

1,918,808Total liabilities and stockholders' equity
$2,550,601
$2,557,868 BIO-TECHNE CORPORATIONCONDENSED CONSOLIDATED CASH FLOWS(In thousands)(Unaudited)








Nine Months Ended

March 31, 

2026
2025CASH FLOWS FROM OPERATING ACTIVITIES





Net earnings
$127,241
$91,078Adjustments to reconcile net earnings to net cash provided by operating activities





Depreciation and amortization

73,218

82,792Costs recognized on sale of acquired inventory

—

554Deferred income taxes

8,045

(18,825)Stock-based compensation expense

36,135

36,283(Gain) Loss on equity method investment

335

169Asset impairment restructuring

3,253

9,961Recovery of assets held-for-sale

(6,789)

(3,655)Other operating activities

(44,781)

(9,002)Net cash provided by (used in) operating activities

196,657

189,355CASH FLOWS FROM INVESTING ACTIVITIES





Proceeds from sale of available-for-sale investments

—

1,085Additions to property and equipment

(20,370)

(26,116)Distributions from Wilson Wolf

4,620

2,653Investment in Spear Bio

—

(15,000)Proceeds from sale of assets held-for-sale

4,617

1,789Net cash provided by (used in) investing activities

(11,133)

(35,589)CASH FLOWS FROM FINANCING ACTIVITIES





Cash dividends

(37,432)

(38,004)Proceeds from stock option exercises

58,193

45,513Long-term debt activity, net

(146,000)

11,000Repurchases of common stock

(24)

(175,674)Taxes paid on RSUs and net share settlements

(10,643)

(6,288)Net cash provided by (used in) financing activities

(135,906)

(163,453)Effect of exchange rate changes on cash and cash equivalents

(1,985)

(1,434)Net increase (decrease) in cash and cash equivalents

47,633

(11,121)Cash and cash equivalents at beginning of period

162,186

151,791Cash and cash equivalents at end of period
$209,819
$140,670Use of Non-GAAP Financial Measures:This press release contains financial measures that have not been calculated in accordance with accounting principles generally accepted in the U.S. (GAAP). We provide these measures as additional information regarding our operating results. We use these non-GAAP measures internally to evaluate our performance and in making financial and operational decisions, including with respect to incentive compensation. We believe that our presentation of these measures provides investors with greater transparency with respect to our results of operations and that these measures are useful for period-to-period comparison of results. Investors are encouraged to review the reconciliations of non-GAAP financial measures used in this press release to their most directly comparable GAAP financial measures as provided with the financial statements attached to this press release.Our non-GAAP financial measure of organic revenue and organic revenue growth represent revenue growth excluding revenue from acquisitions within the preceding 12 months, the impact of foreign currency, the impact of businesses held-for-sale, as well as the impact of partially-owned consolidated subsidiaries. Excluding these measures provides more useful period-to-period comparison of revenue results as it excludes the impact of foreign currency exchange rates, which can vary significantly from period to period, and revenue from acquisitions that would not be included in the comparable prior period. Revenues from businesses held-for-sale are excluded from our organic revenue calculation starting on the date they become held-for-sale as that revenue will not be comparable in future periods. Revenues from partially-owned subsidiaries consolidated in our financial statements are also excluded from our organic revenue calculations, as those revenues are not fully attributable to the Company. There was no revenue from partially-owned consolidated subsidiaries in fiscal years 2026 or 2025.Our non-GAAP financial measures for adjusted gross margin, adjusted operating margin, adjusted EBITDA, and adjusted net earnings, in total and on a per share basis, exclude stock-based compensation, which is inclusive of the employer portion of payroll taxes on those stock awards, the costs recognized upon the sale of acquired inventory, amortization of acquisition intangibles, and restructuring and restructuring-related costs. Stock-based compensation is excluded from adjusted net earnings because of the nature of this charge, specifically the varying available valuation methodologies, subjective assumptions, variety of award types, and unpredictability of amount and timing of employer related tax obligations. The Company excludes amortization of purchased intangible assets, purchase accounting adjustments, including costs recognized upon the sale of acquired inventory, and other non-recurring items including gains or losses on goodwill and long-lived asset impairment charges, and one-time assessments from this measure because they occur as a result of specific events, and are not reflective of our internal investments, the costs of developing, producing, supporting and selling our products, and the other ongoing costs to support our operating structure. Costs related to restructuring and restructuring-related activities, including reducing overhead and consolidating facilities, are excluded because we believe they are not indicative of our normal operating costs.  Additionally, these amounts can vary significantly from period to period based on current activity. The Company also excludes revenue and expense attributable to partially-owned consolidated subsidiaries as well as revenue and expense attributable to businesses held-for-sale in the calculation of our non-GAAP financial measures.The Company's non-GAAP adjusted operating margin, adjusted EBITDA, and adjusted net earnings, in total and on a per share basis, also exclude acquisition related expenses inclusive of the changes in fair value of contingent consideration, and other non-recurring items including certain costs related to the transition to a new CEO, goodwill and long-lived asset impairments, and gains. We also exclude certain litigation charges which are facts and circumstances specific including costs to resolve litigation and legal settlement (gains and losses). In some cases, these costs may be a result of litigation matters at acquired companies that were not probable, inestimable, or unresolved at the time of acquisition.The Company's non-GAAP adjusted EBITDA and adjusted net earnings, in total and on a per share basis, also excludes gains and losses from investments, as they are not part of our day-to-day operating decisions (excluding our equity method investment in Wilson Wolf as it is certain to be acquired in the future) and certain adjustments to income tax expense. Additionally, gains and losses from investments that are either isolated or cannot be expected to occur again with any predictability are excluded. The Company independently calculates a non-GAAP adjusted tax rate to be applied to the identified non-GAAP adjustments considering the impact of discrete items on these adjustments and the jurisdictional mix of the adjustments. In addition, the tax impact of other discrete and non-recurring charges which impact our reported GAAP tax rate are adjusted from net earnings. We believe these tax items can significantly affect the period-over-period assessment of operating results and not necessarily reflect costs and/or income associated with historical trends and future results.  View original content to download multimedia:https://www.prnewswire.com/news-releases/bio-techne-releases-third-quarter-fiscal-2026-results-302763516.htmlSOURCE Bio-Techne Corporation Original: Bio-Techne Releases Third Quarter Fiscal 2026 Results

Bio-Techne to Present at the Bank of America Securities 2026 Global Healthcare ConferenceMay 4, 2026 7:00 AM
PR Newswire (US)

MINNEAPOLIS, May 4, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Kim Kelderman, President and Chief Executive Officer, will present at the Bank of America Securities 2026 Global Healthcare Conference on Tuesday, May 12, 2026, at 9:20 a.m. PDT. A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar.About Bio-Techne
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company headquartered in Minnesota,?celebrating 50 years of empowering scientific?and?diagnostic?communities?to reach?better answers. The company provides high-quality reagents, analytical instruments,?and?precision diagnostics.?Its portfolio is organized into three customer-focused brands:?R&D Systems™, Bio-Techne Spatial™, and Bio-Techne?Diagnostics™, reflecting?the scientific journey from discovery to?translational?research?to clinical decision-making.?Bio-Techne operates?in?34 locations worldwide and employs approximately 3,100 people. In fiscal year 2025, the company generated over?$1.2 billion?in net sales.?Its more?than 500,000 products are used globally by academic researchers, biopharmaceutical and biotechnology companies, and clinical diagnostic laboratories.For more information on Bio-Techne and its brands, please visit?www.bio-techne.com?or follow the company on social media at?LinkedIn,?X,?or?YouTube.Contact: David Clair, Vice President, Investor Relations
david.clair@bio-techne.com





View original content to download multimedia:https://www.prnewswire.com/news-releases/bio-techne-to-present-at-the-bank-of-america-securities-2026-global-healthcare-conference-302760526.htmlSOURCE Bio-Techne Corporation

Original: Bio-Techne to Present at the Bank of America Securities 2026 Global Healthcare Conference

Bio-Techne Introduces Streamlined Brand Architecture to Help Customers Navigate Solutions Faster and With Greater ClarityApril 16, 2026 8:00 AM
PR Newswire (Canada)

Bio-Techne introduces a streamlined brand architecture that organizes its technologies into three focused portfolio brands:
R&D Systems™, Bio-Techne Spatial™, and Bio-Techne Diagnostics™.The new brand structure reflects the scientific journey, connecting early discoveries to translational insight to clinical decision-making.The portfolio brands will debut at the AACR Annual Meeting 2026 and AAI's IMMUNOLOGY 2026™.MINNEAPOLIS, April 16, 2026 /CNW/ -- Bio-Techne Corporation (NASDAQ: TECH), a global provider of life science research tools, analytical instruments, and diagnostics, today announced a streamlined brand architecture designed to enable scientists and clinicians to more easily find the answers they need based on their application and stage of research.The company has organized its products and technologies under three focused portfolio brands — R&D Systems™, Bio-Techne Spatial™, and Bio-Techne Diagnostics™ — aligning its solutions with the way modern science progresses from early discovery through translational insights to clinical diagnostics.For 50 years, Bio-Techne has driven scientific discovery and clinical innovation through a diversified portfolio of industry-leading solutions—from high-quality proteins, antibodies, and small molecules to advanced technologies, including protein analytical instruments and spatial biology platforms, that enable breakthrough research."At Bio-Techne, our focus is empowering scientists and clinicians to achieve better answers that lead to more breakthroughs," said Kim Kelderman, President and Chief Executive Officer of Bio-Techne. "By aligning our portfolio with the fast-paced progression of scientific research, we make it easier for customers to access the solutions they need to advance their work and accelerate scientific progress.Kelderman adds, "Our updated brand structure strengthens our position as a trusted scientific partner, bringing greater alignment across our expanding portfolio and reinforcing our mission to improve the quality of life by catalyzing advances in science and medicine."R&D Systems: Empowering Better Answers in Scientific DiscoveryThe R&D Systems1 portfolio brings together Bio-Techne's trusted proteins, antibodies, immunoassays, small molecules and innovative instruments used by scientists worldwide. R&D Systems solutions help researchers generate reproducible results, validate discoveries, and advance early-stage research towards clinical application with confidence. As the starting point of the scientific journey, R&D Systems provides dependable tools needed to explore, experiment, and uncover new biological insights. R&D Systems also provides key GMP-grade reagents and tools essential for advancing cell and gene therapy workflows.Bio-Techne Spatial: Empowering Better Answers in Translational Research The Bio-Techne Spatial1 portfolio leverages technologies that help researchers and clinicians translate biology and disease context across both the gold-standard RNAscope™ in situ hybridization technology and the automated COMET™ spatial hyperplex platform. Bio-Techne Spatial solutions enable scalable, high-resolution visualization of RNA and protein with multiomic analysis, delivering exceptional sensitivity and precision to reveal differences in cell structure, identify clinically relevant biomarkers, inform pathology-driven research questions and accelerate therapeutic discovery.Bio-Techne Diagnostics: Empowering Better Answers in DiagnosticsThe Bio-Techne Diagnostics1 portfolio provides clinical laboratories and IVD manufacturers with assay kits, IVD-grade reagents, antibodies, molecular controls, calibrators, and proficiency-testing materials needed to design, develop, and validate reliable diagnostic assays. The portfolio supports the full lifecycle of assay development from early design through deployment at scale. By delivering high-quality raw materials and comprehensive assay solutions, Bio-Techne Diagnostics helps ensure accuracy, strengthens clinical decision-making, and ultimately contributes to improved patient outcomes.Together, these three portfolios create a clearer, more connected path for customers by providing a streamlined, end-to-end view of Bio-Techne's solutions, aligning tools and technologies from discovery through translation to clinical diagnostics and accelerating scientific and clinical progress.Bio-Techne will highlight its newly aligned portfolio at several upcoming scientific meetings, including the American Association for Cancer Research (AACR) Annual Meeting in San Diego and IMMUNOLOGY2026™ in Boston, USA.Visit R&D Systems and Bio-Techne Spatial at AACR
Visit R&D Systems and Bio-Techne Spatial at AAIABOUT BIO-TECHNE Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company headquartered in Minnesota, celebrating 50 years of empowering scientific and diagnostic communities to reach better answers. The company provides high-quality reagents, analytical instruments, and precision diagnostics.Its portfolio is organized into three customer-focused brands: R&D Systems™, Bio-Techne Spatial™, and Bio-Techne Diagnostics™, reflecting the scientific journey from discovery to translational research to clinical decision-making.Bio-Techne operates in 34 locations worldwide and employs approximately 3,100 people. In fiscal year 2025, the company generated over $1.2 billion in net sales. Its more than 500,000 products are used globally by academic researchers, biopharmaceutical and biotechnology companies, and clinical diagnostic laboratories.For more information on Bio-Techne and its brands, please visit www.bio-techne.com or follow the Company on social media at LinkedIn, X, or YouTube.1 R&D Systems™ now includes the legacy brands Novus Biologicals™, Tocris Bioscience™, and ProteinSimple™; Bio-Techne Spatial now includes the legacy brands Lunaphore™, and Advanced Cell Diagnostics™; Bio-Techne Diagnostics now includes Asuragen®, Bionostics, Cliniqa, RNA Medical®, and R&D Systems™ Clinical Controls.MEDIA CONTACTSCorporate Communications
media.relations@bio-techne.comDavid Clair, Vice President Investor Relations
ir@bio-techne.com 





View original content to download multimedia:https://www.prnewswire.com/news-releases/bio-techne-introduces-streamlined-brand-architecture-to-help-customers-navigate-solutions-faster-and-with-greater-clarity-302744696.htmlSOURCE Bio-Techne Corporation

Original: Bio-Techne Introduces Streamlined Brand Architecture to Help Customers Navigate Solutions Faster and With Greater Clarity

Bio-Techne to Host Conference Call on May 6, 2026, to Announce Third Quarter Fiscal 2026 Financial ResultsApril 14, 2026 7:00 AM
PR Newswire (US)

MINNEAPOLIS, April 14, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host a conference call and webcast on Wednesday, May 6, 2026, at 8:00 a.m. CDT to review its third quarter fiscal 2026 financial results.Access to the discussion may be obtained as follows:Time:8:00 a.m. CDTDate:May 6, 2026Dial-in:1-800-343-4136 or 1-203-518-9843 (for international callers)Conference ID:TECHQ3Webcast:https://investors.bio-techne.com/ir-calendarA recorded rebroadcast will be available for interested parties unable to participate in the live conference call by dialing 1-844-512-2921 or 1-412-317-6671 (for international callers) and referencing Conference ID 11161556.The replay will be available from 11:00 a.m. CDT on Wednesday, May 6, 2026, until 11:00 p.m. CDT on Saturday, June 6, 2026.About Bio-Techne Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With hundreds of thousands of products in its portfolio, Bio-Techne generated over $1.2 billion in net sales in fiscal 2025 and has approximately 3,100 employees worldwide. For more information on Bio-Techne and its brands, please visit?https://www.bio-techne.com?or follow the Company on social media at?LinkedIn,?X, or?YouTube.Contact:David Clair, Vice President, Investor Relationsdavid.clair @Yenlady-4416 





View original content to download multimedia:https://www.prnewswire.com/news-releases/bio-techne-to-host-conference-call-on-may-6-2026-to-announce-third-quarter-fiscal-2026-financial-results-302741254.htmlSOURCE Bio-Techne Corporation

Original: Bio-Techne to Host Conference Call on May 6, 2026, to Announce Third Quarter Fiscal 2026 Financial Results

Bio-Techne Advances Spatial Biology with Modular Expansion of COMET™ SuiteMarch 25, 2026 6:30 AM
PR Newswire (US)

New SPYRE™ Focus Panels (Stroma and Vessel) broaden modular panel options, enabling deeper targeted insights in spatial biology workflows. SPYRE™ Amplification Kits leverage sequential and enhanced layered amplification (seqLA™) technology enabling improved detection of low-abundance and challenging targets. Enhancements strengthen the fully integrated COMET spatial biology ecosystem, supporting increased consumables adoption and panel expansion.MINNEAPOLIS, March 25, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a global provider of life science tools, reagents and diagnostic products, today announced the expansion of its COMET™ solution portfolio with the addition of the new SPYRE™ Focus Panels and SPYRE™ Amplification Kits. Together, these strengthen the COMET technology modular, automated spatial biology workflow, delivering expanded flexibility, greater sensitivity, and enabling deeper, more focused interrogation of biologically meaningful data from initial assay design through final interpretation. To support these updates, new features of HORIZON™ Image Analysis Software have also been introduced, tailored for COMET hyperplex images using the new SPYRE tools, further streamlining tissue analysis."Researchers need tools that make it easier to extract meaningful answers from complex tissue samples," said Steve Crouse, President of Bio-Techne's Diagnostics and Spatial Biology Segment. "Innovation is one of Bio-Techne's key differentiators, and SPYRE Focus Panels and SPYRE Amplification Kits reflect that strength. By incorporating these capabilities into the COMET Suite, we are giving researchers a more flexible, faster, and higher sensitivity workflow that enables researchers to achieve deeper insights with greater confidence."SPYRE™ Antibody Panels, including the newly introduced Stroma and Vessel Focused Panels, are modular antibody panels designed to enable flexible multiplex assay design while reducing optimization time. Panels leverage validated antibodies with ready-to-use protocols to streamline setup while maintaining flexibility to incorporate markers from a lab's own antibody library. SPYRE™ Amplification Kits use seqLA™ technology to improve the detection of low-abundance and difficult-to-detect targets."Utilizing the pre-optimized SPYRE panel has not only increased the capacity of conventional multiplex immunofluorescence but also enabled a one-day experimental protocol," said Prof. Joanne Edwards, Professor of Translational Cancer Pathology, University of Glasgow. "The COMET workflow is straightforward and flexible, allowing us to easily integrate our own antibodies of interest. This technology provides insightful data, facilitating the simultaneous investigation of tumor and microenvironment cells within the same sample."Together, SPYRE Focus Panels and SPYRE Amplification Kits strengthen Bio-Techne's commitment to deliver a fully integrated, modular, and automated spatial biology ecosystem that accelerates research and preclinical therapeutic development. These innovations continue to empower researchers to generate richer data and deeper biological understanding from every tissue sample.ABOUT BIO-TECHNE: 
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for?the research?and clinical diagnostic communities. Bio-Techne products?assist?scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for?accurate?clinical tests and diagnoses. With hundreds of thousands of products in its portfolio, Bio-Techne generated over?$1.2 billion?in net sales in fiscal 2025 and has approximately 3,100 employees worldwide. For more information, visit?www.bio-techne.com?or follow the Company on social media at?LinkedIn,?X?and?YouTube.MEDIA CONTACTS: Corporate Communications 
media.relations@bio-techne.comDavid Clair, Vice President Investor Relations
ir@bio-techne.com





View original content to download multimedia:https://www.prnewswire.com/news-releases/bio-techne-advances-spatial-biology-with-modular-expansion-of-comet-suite-302724287.htmlSOURCE Bio-Techne Corporation

Original: Bio-Techne Advances Spatial Biology with Modular Expansion of COMET™ Suite

Bio-Techne to Present at Upcoming Investor ConferencesFebruary 24, 2026 7:00 AM
PR Newswire (US)

MINNEAPOLIS, Feb. 24, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that it will present at the following investor conferences:TD Cowen 46th Annual Health Care Conference
March 3, 2026
11:10 AM ESTLeerink Partners Global Healthcare Conference
March 10, 2026
8:40 AM EDTA live webcast of the presentations can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar.About Bio-Techne
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With hundreds of thousands of products in its portfolio, Bio-Techne generated over $1.2 billion in net sales in fiscal 2025 and has approximately 3,100 employees worldwide. For more information on Bio-Techne and its brands, please visit https://www.bio-techne.com or follow the Company on social media at: LinkedIn, X or YouTube.Contact:David Clair, Vice President, Investor Relations
david.clair@bio-techne.com





View original content to download multimedia:https://www.prnewswire.com/news-releases/bio-techne-to-present-at-upcoming-investor-conferences-302694785.htmlSOURCE Bio-Techne Corporation

Original: Bio-Techne to Present at Upcoming Investor Conferences

Bio-Techne's Ella Platform Achieves CE-IVD Marking Expanding Access to Rapid, Cartridge-Based Immunoassays for European Clinical LaboratoriesFebruary 16, 2026 6:30 AM
PR Newswire (US)

Ella benchtop instrument is now CE-IVD marked and available for sale in the EUEnables diagnostic assay developers to leverage a simplified platform that delivers speed and reproducible results with minimal hands-on timeProvides confidence for use in clinical trials and in-house test development   MINNEAPOLIS , Feb. 16, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a global provider of life science tools, reagents, and diagnostic products, today announced that the Ella benchtop immunoassay platform has received CE-IVD marking1 and is now available for sale in the European Union. This achievement brings Ella's hallmark ease of use, speed and reproducibility to clinical settings, helping laboratories streamline workflows and support timely decision-making.Ella is a compact, cartridge-based immunoassay system that delivers accurate biomarker results in under 90 minutes with minimal hands-on time. By simplifying the manual steps of traditional immunoassays, Ella reduces operator variability and provides high-quality, reproducible data suitable for both translational research and clinical applications.The platform is compatible with Simple Plex™ assays, which remain for research use only, and are powered by R&D Systems antibodies and proteins. With more than 390 analytes across neuroscience, immunology, oncology, and cell and gene therapy, the Simple Plex portfolio enables researchers to maintain consistency and data quality while working efficiently across a wide range of applications."Ella's CE-IVD certification marks a significant step forward in advancing precision diagnostics," said Will Geist, President of Bio-Techne's Protein Sciences Segment. "It reflects our commitment to providing innovative tools that enhance clinical decision-making and improve patient outcomes."With CE-IVD marking now in place, hospitals, clinical laboratories, or other European organizations may use Ella as a validated platform for in-house test development, clinical trials, or other translational activities. Diagnostic assay developers may also develop clinical applications on the Ella CE-IVD validated platform. The certification enhances confidence in Ella's performance and supports Bio-Techne's long-term goal to advance precision medicine by providing dependable, standardized solutions for biomarker detection.Learn more about the Ella CE-IVD mark and the Ella platform by visiting?bio-techne.com/Ella.1 CE-IVD marking signifies that a product complies with the European Union's In Vitro Diagnostic Regulation (IVDR, Regulation (EU)2017/746), confirming its safety, performance, and reliability for clinical use.About Bio-Techne: 
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With hundreds of thousands of products in its portfolio, Bio-Techne generated over $1.2 billion in net sales in fiscal 2025 and has approximately 3,100 employees worldwide. For more information, visit https://www.bio-techne.com or follow the Company on social media at LinkedIn, X and YouTube. Media Contacts:
Corporate Communications
media.relations@bio-techne.comDavid Clair, Vice President, Investor Relations
IR@bio-techne.com





View original content to download multimedia:https://www.prnewswire.com/news-releases/bio-technes-ella-platform-achieves-ce-ivd-marking-expanding-access-to-rapid-cartridgebased-immunoassays-for-european-clinical-laboratories-302688454.htmlSOURCE Bio-Techne Corporation

Original: Bio-Techne's Ella Platform Achieves CE-IVD Marking Expanding Access to Rapid, Cartridge-Based Immunoassays for European Clinical Laboratories

Bio-Techne Tops Forecasts as Adjusted EPS Climbs 10%February 4, 2026 10:13 AM
IH Market News
Bio-Techne Corporation (NASDAQ:TECH) reported second-quarter fiscal 2026 results that showed steady revenue but stronger profitability, with adjusted earnings per share rising 10% year on year and beating market expectations.The company posted adjusted EPS of $0.46 for the quarter, up from $0.42 a year earlier and ahead of the analyst consensus of $0.43. Shares were little changed in after-hours trading following the release.Quarterly revenue totaled $295.9 million, flat compared with the prior year but above analysts’ forecasts of $290.42 million. Despite the lack of top-line growth, Bio-Techne delivered improved earnings as productivity gains and cost-control measures lifted its adjusted operating margin to 31.1%, an increase of 100 basis points from last year.“I am pleased with the Bio-Techne team’s continued execution in a stabilizing operating environment,” said Kim Kelderman, President and Chief Executive Officer. “For the fourth consecutive quarter we delivered double-digit growth in our biggest end market, large pharma.”Within the business, the Protein Sciences segment—which provides specialized proteins and platforms used in protein analysis—recorded a 2% increase in revenue to $215.1 million. By contrast, revenue in the Diagnostics and Spatial Biology segment declined 4% to $81.2 million.On a GAAP basis, earnings per share improved to $0.24 from $0.22 in the same quarter last year. The company also pointed to solid commercial execution in China and the broader Asia-Pacific region, which delivered growth for a third straight quarter, alongside improving trends in biotech customers and signs of stabilization among U.S. academic institutions.Bio-Techne Corporation stock price

Original: Bio-Techne Tops Forecasts as Adjusted EPS Climbs 10%

Bio-Techne Declares DividendFebruary 4, 2026 6:30 AM
PR Newswire (US)

MINNEAPOLIS, Feb. 4, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended December 31, 2025. The quarterly dividend will be payable February 27, 2026, to all common shareholders of record on February 16, 2026. Future cash dividends will be considered by the Board of Directors on a quarterly basis.Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With thousands of products in its portfolio, Bio-Techne generated over $1.2 billion in net sales in fiscal 2025 and has approximately 3,100 employees worldwide. For more information on Bio-Techne and its brands, please visit www.bio­-techne.com.Forward Looking Statements:
Our press releases may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Such statements involve risks and uncertainties that may affect the actual results of operations. Forward looking statements in this press release include statements regarding potential future repurchase of Bio-Techne common stock. The following important factors, among others, have affected and, in the future, could affect the Company's actual results and future share price: the effect of new branding and marketing initiatives, the integration of new businesses and leadership, the introduction and acceptance of new products, the funding and focus of the types of research by the Company's customers, the impact of the growing number of producers of biotechnology research products and related price competition, general economic conditions, customer site closures or supply chain issues, the impact of currency exchange rate fluctuations, and the costs and results of research and product development efforts of the Company and of companies in which the Company has invested or with which it has formed strategic relationships.For additional information concerning such factors, see the section titled "Risk Factors" in the Company's annual report on Form 10-K and quarterly reports on Form 10-Q as filed with the Securities and Exchange Commission. We undertake no obligation to update or revise any forward-looking statements we make in our press releases due to new information or future events. Investors are cautioned not to place undue emphasis on these statements.Contact:David Clair, Vice President, Investor Relations
David.Clair@bio-techne.com
612-656-4416





View original content to download multimedia:https://www.prnewswire.com/news-releases/bio-techne-declares-dividend-302678498.htmlSOURCE Bio-Techne Corporation

Original: Bio-Techne Declares Dividend

Bio-Techne Releases Second Quarter Fiscal 2026 ResultsFebruary 4, 2026 6:30 AM
PR Newswire (US)

MINNEAPOLIS, Feb. 4, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today reported its financial results for the second quarter ending December 31, 2025.Second Quarter FY2026 HighlightsSecond quarter revenue was $295.9 million with reported and organic growth flat to prior year.GAAP earnings per share (EPS) was $0.24 versus $0.22 one year ago. Delivered adjusted EPS of $0.46 compared to $0.42 one year ago.Ongoing productivity and cost containment initiatives led to 31.1% adjusted operating margin, an increase of 100 basis points compared to the prior year period.Strong commercial execution and improving end-markets drove growth in the China/APAC region for the third consecutive quarter."I am pleased with the Bio-Techne team's continued execution in a stabilizing operating environment," said Kim Kelderman, President and Chief Executive Officer of Bio-Techne. "For the fourth consecutive quarter we delivered double-digit growth in our biggest end market, large pharma. That momentum, together with improving performance in biotech, continued stabilization among our U.S. academic customers, and ongoing growth in Asia, drove results that were largely in line with our expectations."Kelderman continued, "In 2026, Bio-Techne proudly celebrates its 50th anniversary. Over the past five decades, we have built a durable, differentiated portfolio that serves high-growth, high-value applications and accelerates innovation in science and medicine. I am incredibly proud of what we have accomplished to date. As we look ahead, our strong position enables us to drive continued innovation, growth, and value for all our stakeholders."Conference Call Bio-Techne will host an earnings conference call today, February 4, 2026, at 8:00 a.m. CST. To listen, please dial 1-800-579-2543 or 1-785-424-1789 (for international callers), and reference conference ID TECHQ2. The earnings call can also be accessed via webcast through the following link https://investors.bio-techne.com/ir-calendar.A recorded rebroadcast will be available for interested parties unable to participate in the live conference call by dialing 1-844-512- 2921 or 1-412-317-6671 (for international callers) and referencing Conference ID 11160826. The replay will be available from 11:00 a.m. CST on Wednesday, February 4, 2026, until 11:00 p.m. CST on Wednesday, March 4, 2026.Second Quarter Fiscal 2026RevenueNet sales and organic revenue for the second quarter were flat at $295.9 million compared to the prior year. Foreign currency exchange had a favorable impact of 2%, and non-recurring prior year revenue from a business held-for-sale had an unfavorable impact of 2%.GAAP Earnings ResultsGAAP EPS was $0.24 per diluted share versus $0.22 in the same quarter last year. GAAP operating income for the second quarter of fiscal 2026 increased 15% to $54.5 million compared to $47.4 million in the second quarter of fiscal 2025. GAAP operating margin was 18.4% compared to 16.0% in the second quarter of fiscal 2025. Current quarter GAAP operating margin was favorably impacted by ongoing profitability initiatives and the Exosome Diagnostics divestiture, partially offset by unfavorable product mix.Non-GAAP Earnings ResultsAdjusted EPS increased to $0.46 per diluted share compared to $0.42 in the same quarter last year. Adjusted operating income increased to $92.0 million in the second quarter of fiscal 2026 compared to second quarter of fiscal 2025 adjusted operating income of $88.7 million. Adjusted operating margin was 31.1% for the second quarter of fiscal 2026 compared to 30.1% in the second quarter of fiscal 2025. Adjusted operating margin was favorably impacted by ongoing profitability initiatives and the Exosome Diagnostics divestiture, partially offset by unfavorable product mix.Segment ResultsManagement uses adjusted operating results to monitor and evaluate performance of the Company's business segments, as highlighted below.Protein Sciences SegmentThe Company's Protein Sciences segment is one of the world's leading suppliers of specialized proteins such as cytokines and growth factors, immunoassays, antibodies and reagents, to the biopharma and academic research communities. Additionally, the segment provides an array of platforms essential in various areas of protein analysis. The Protein Sciences segment's second quarter fiscal 2026 net sales were $215.1 million, an increase of 2% from $211.6 million for the second quarter of fiscal 2025. As of December 31, 2023, a business within the Protein Sciences segment met the criteria as held-for-sale; this held-for-sale business has been excluded from the segment's operating results for both periods presented. Organic revenue decreased 1% for the second quarter of fiscal 2026, with foreign currency exchange having a favorable impact of 3%. The Protein Sciences segment's operating margin decreased to 39.3% in the second quarter of fiscal 2026 compared to 41.2% in the second quarter of fiscal 2025. The segment's operating margin decreased primarily due to unfavorable product mix, partially offset by ongoing profitability initiatives.Diagnostics and Spatial Biology SegmentThe Company's Diagnostics and Spatial Biology segment develops and provides spatial biology products, carrier screening and oncology kits. The Diagnostics and Spatial Biology segment also provides blood chemistry and blood gas quality controls, hematology instrument controls, immunoassays and other bulk and custom reagents for the in vitro diagnostic market. The Diagnostics and Spatial Biology segment's second quarter fiscal 2026 net sales were $81.2 million, a decrease of 4% from $84.1 million for the second quarter of fiscal 2025. As of June 30, 2025, a business within the Diagnostics and Spatial Biology segment met the criteria as held-for-sale; this held-for-sale business has been excluded from the segment's fiscal 2026 operating results. Organic revenue growth was 3% for the second quarter of fiscal 2026, with foreign exchange having a favorable impact of 1%. The held-for-sale business had an unfavorable impact of 8%. The Diagnostics and Spatial Biology segment's operating margin increased to 10.4% in the second quarter of fiscal 2026 compared to 3.9% in the second quarter of fiscal 2025. The segment's operating margin was favorably impacted by the Exosome Diagnostics divestiture and ongoing profitability initiatives, partially offset by unfavorable product mix.About Bio-TechneBio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With thousands of products in its portfolio, Bio-Techne generated over $1.2 billion in net sales in fiscal 2025 and has approximately 3,100 employees worldwide. For more information on Bio-Techne and its brands, please visit www.bio­techne.com.Forward Looking Statements:This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act. These statements use words and variations of words, such as "will," "plan," "continue," "believe," "outlook," "expect," and "predict." These statements are made as of the date of this press release, are based on current expectations of future events, and thus are inherently subject to a number of risks and uncertainties, many of which involve factors or circumstances beyond the Company's control. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the Company's expectations and projections. These risks, uncertainties, and other factors include, without limitation: the effect of new branding and marketing initiatives, the integration of new businesses and leadership, the introduction and acceptance of new products, the funding and focus of the types of research by the Company's customers, the impact of the growing number of producers of biotechnology research products and related price competition, general economic conditions, the impact of currency exchange rate fluctuations, and the costs and results of research and product development efforts of the Company and of companies in which the Company has invested or with which it has formed strategic relationships.For additional information concerning these risks, uncertainties, and other factors, see the section titled "Risk Factors" in the Company's most recent annual report on Form 10-K as filed with the Securities and Exchange Commission. We undertake and we expressly disclaim any obligation to update or revise any forward-looking statements due to new information, changed assumptions, or future events, except as required by law. Investors are cautioned not to place undue reliance on forward-looking statements.Non-GAAP Financial Measures:The Company's financial statements are prepared in accordance with accounting principles generally accepted in the U.S. (GAAP). This press release contains financial measures that have not been calculated in accordance with GAAP. These non-GAAP measures include:Organic revenue and organic revenue growthAdjusted gross marginEarnings before interest, taxes, depreciation, and amortization (EBITDA)Adjusted EBITDAAdjusted operating incomeAdjusted operating marginAdjusted tax rateAdjusted net earningsAdjusted diluted earnings per shareThese non-GAAP measures should not be considered in insolation or as a substitute for any measure derived in accordance with GAAP and may also be inconsistent with similar measures presented by other companies. Reconciliations of these measures to the applicable most closely comparable GAAP measures, and reasons for the Company's use of these measures, are presented in the attached pages.Contact:       David Clair, Vice President, Investor Relations
David.Clair@bio-techne.com
612-656-4416 BIO-TECHNE CORPORATIONCONDENSED CONSOLIDATED STATEMENTS OF EARNINGS(In thousands, except per share data)(Unaudited)














Quarter Ended
Six Months Ended

December 31, 
December 31, 

2025
2024
2025
2024Net sales
$295,877
$297,031
$582,432
$586,489Cost of sales

104,600

103,145

203,043

209,586Gross margin

191,277

193,886

379,389

376,903Operating expenses:











Selling, general and administrative

113,691

121,451

229,904

240,612Research and development

23,125

25,016

47,366

48,885Total operating expenses

136,816

146,467

277,270

289,497Operating income

54,461

47,419

102,119

87,406Other income (expense)

(3,677)

(4,543)

(3,344)

(4,359)Earnings before income taxes

50,784

42,876

98,775

83,047Income taxes

12,775

7,986

22,581

14,557Net earnings
$38,009
$34,890
$76,194
$68,490Earnings per share:











Basic
$0.24
$0.22
$0.49
$0.43Diluted
$0.24
$0.22
$0.49
$0.42Weighted average common shares outstanding:











Basic

155,839

158,431

155,652

158,481Diluted

156,999

160,626

156,750

161,353 BIO-TECHNE CORPORATIONRECONCILIATION OF ADJUSTED GROSS MARGIN AND ADJUSTED GROSS MARGIN PERCENTAGE(In thousands)(Unaudited)















Quarter Ended
Six Months Ended


December 31, 
December 31, 


2025
2024
2025
2024
Total consolidated net sales
$295,877
$297,031
$582,432
$586,489
Business held-for-sale(1)

—

1,849

5,439

4,152
Revenue from recurring operations
$295,877
$295,182
$576,993
$582,337














Gross margin - GAAP
$191,277
$193,886
$379,389
$376,903
Gross margin percentage - GAAP

64.6%
65.3%
65.1%
64.3%













Identified adjustments:












Costs recognized upon sale of acquired inventory
$—
$185
$—
$373
Amortization of intangibles

9,473

10,630

18,912

22,410
Stock-based compensation, inclusive of employer taxes

467

395

852

667
Restructuring and restructuring-related costs

1,526

2,691

3,604

7,589
Impact of business held-for-sale(1)

—

376

(2,581)

(182)
Adjusted gross margin
$202,743
$208,163
$400,176
$407,760
Adjusted gross margin percentage(2)

68.5%
70.5%
69.4%
70.0%

(1)December 31, 2024 amounts relate to the Protein Sciences segment business that met the held-for-sale criteria on December 31, 2023. December 31, 2025 amounts relate to the Diagnostics and Spatial Biology segment business that met the held-for-sale criteria on June 30, 2025.(2)Adjusted gross margin percentage excludes both revenue and gross margin of the businesses that met the held-for-sale criteria during the respective periods. BIO-TECHNE CORPORATIONRECONCILIATION OF GAAP NET INCOME TO ADJUSTED EBITDA(In thousands)(Unaudited)


Quarter Ended
Six Months Ended

December 31, 
December 31, 

2025
2024
2025
2024Net earnings
$38,009
$34,890
$76,194
$68,490Net interest expense (income)

1,274

800

3,235

2,050Depreciation and amortization

24,709

27,084

49,049

55,221Income taxes

12,775

7,986

22,581

14,557EBITDA

76,767

70,760

151,059

140,318Amortization of Wilson Wolf intangible assets

2,490

2,489

4,979

4,979Acquisition related expenses and other

2,239

2,324

5,747

4,186Certain litigation charges

2,140

1,386

4,549

1,678Stock-based compensation, inclusive of employer taxes

14,198

15,238

26,294

25,875Restructuring and restructuring-related costs

3,739

3,287

11,249

14,309Investment (gain) loss and other non-operating (income) loss

1,842

—

(304)

—Recovery of assets held-for-sale

—

—

(6,789)

—Impact of business held-for-sale(1)

—

627

2,573

479Adjusted EBITDA
$103,415
$96,111
$199,357
$191,824

(1) December 31, 2024 amounts relate to the Protein Sciences segment business that met the held-for-sale criteria on December 31, 2023. December 31, 2025 amounts relate to the Diagnostics and Spatial Biology segment business that met the held-for-sale criteria on June 30, 2025. BIO-TECHNE CORPORATIONRECONCILIATION OF ADJUSTED OPERATING INCOME AND ADJUSTED OPERATING MARGIN PERCENTAGE(In thousands)(Unaudited)


Quarter Ended
Six Months Ended


December 31, 
December 31, 


2025
2024
2025
2024
Total consolidated net sales
$295,877
$297,031
$582,432
$586,489
Business held-for-sale(1)

—

1,849

5,439

4,152
Revenue from recurring operations
$295,877
$295,182
$576,993
$582,337














Operating income - GAAP
$54,461
$47,419
$102,119
$87,406
Operating income percentage - GAAP

18.4%
16.0%
17.5%
14.9%













Identified adjustments:












Amortization of intangibles

15,379

18,559

30,729

38,300
Acquisition related expenses and other

2,093

2,195

5,444

3,896
Certain litigation charges

2,140

1,386

4,549

1,678
Stock-based compensation, inclusive of employer taxes

14,198

15,238

26,294

25,875
Restructuring and restructuring-related costs

3,739

3,287

11,249

14,309
Recovery of assets held-for-sale

—

—

(6,789)

—
Impact of business held-for-sale(1)

—

627

2,573

479
Adjusted operating income
$92,010
$88,711
$176,168
$171,943
Adjusted operating margin percentage(2)

31.1%
30.1%
30.5%
29.5%

(1)December 31, 2024 amounts relate to the Protein Sciences segment business that met the held-for-sale criteria on December 31, 2023. December 31, 2025 amounts relate to the Diagnostics and Spatial Biology segment business that met the held-for-sale criteria on June 30, 2025.(2)Adjusted operating margin percentage excludes both revenue and operating margin for the businesses that met the held-for-sale criteria during the respective periods. BIO-TECHNE CORPORATIONRECONCILIATION OF NON-GAAP ADJUSTED TAX RATE(In percentages)(Unaudited)


Quarter Ended
Six Months Ended

December 31, 
December 31, 

2025
2024
2025
2024GAAP effective tax rate
25.2%
18.6%
22.9%
17.5%Discrete items
0.5

5.1

3.3

6.1
Annual forecast update
0.5

(0.1)

—

—
Long-term GAAP tax rate
26.2%
23.6%
26.2%
23.6%Rate impact items











Stock based compensation
(2.9)%
(2.8)%
(2.8)%
(2.9)%Other
(1.0)

0.7

(1.1)

0.8
Total rate impact items
(3.9)%
(2.1)%
(3.9)%
(2.1)%Non-GAAP adjusted tax rate
22.3%
21.5%
22.3%
21.5% BIO-TECHNE CORPORATIONRECONCILIATION OF ADJUSTED NET EARNINGS AND ADJUSTED EARNINGS PER SHARE(In thousands, except per share data)(Unaudited)


Quarter Ended
Six Months Ended

December 31, 
December 31, 

2025
2024

2025
2024
Net earnings before taxes - GAAP
$50,784
$42,876

$98,775
$83,047
Identified adjustments:













Amortization of intangibles

15,379

18,559


30,729

38,300
Amortization of Wilson Wolf intangible assets

2,490

2,489


4,979

4,979
Acquisition related expenses and other

2,239

2,324


5,747

4,186
Certain litigation charges

2,140

1,386


4,549

1,678
Stock-based compensation, inclusive of employer taxes

14,198

15,238


26,294

25,875
Restructuring and restructuring-related costs

3,739

3,287


11,249

14,309
Investment (gain) loss and other non-operating (income) loss

1,842

—


(304)

—
Recovery of assets held-for-sale

—

—


(6,789)

—
Impact of business held-for-sale(1)

—

627


2,573

479
Net earnings before taxes - Adjusted
$92,811
$86,786

$177,802
$172,853
Non-GAAP tax rate

22.3%
21.5%

22.3%
21.5%Non-GAAP tax expense
$20,697
$18,659

$39,650
$37,195
Non-GAAP adjusted net earnings
$72,114
$68,127

$138,152
$135,658
Earnings per share - diluted - Adjusted
$0.46
$0.42

$0.88
$0.84


(1)December 31, 2024 amounts relate to the Protein Sciences segment business that met the held-for-sale criteria on December 31, 2023. December 31, 2025 amounts relate to the Diagnostics and Spatial Biology segment business that met the held-for-sale criteria on June 30, 2025. BIO-TECHNE CORPORATIONSEGMENT REVENUE(In thousands)(Unaudited)


Quarter Ended
Six Months Ended

December 31, 
December 31, 

2025
2024
2025
2024Protein Sciences segment revenue
$215,084
$211,551
$417,272
$416,086Diagnostics and Spatial Biology segment revenue

81,180

84,135

160,638

167,327Other revenue(1)

—

1,849

5,439

4,152lntersegment revenue

(387)

(504)

(917)

(1,076)Consolidated revenue
$295,877
$297,031
$582,432
$586,489

(1)December 31, 2024 amounts relate to the Protein Sciences segment business that met the held-for-sale criteria on December 31, 2023. December 31, 2025 amounts relate to the Diagnostics and Spatial Biology segment business that met the held-for-sale criteria on June 30, 2025. BIO-TECHNE CORPORATIONSEGMENT OPERATING INCOME(In thousands)(Unaudited)


Quarter Ended
Six Months Ended

December 31, 
December 31,

2025
2024
2025
2024Protein Sciences segment operating income
$84,615
$87,112
$162,328
$167,653Diagnostics and Spatial Biology segment operating income

8,432

3,240

17,310

7,517Segment operating income

93,047

90,352

179,638

175,170Corporate general, selling, and administrative

(1,037)

(1,641)

(3,470)

(3,227)Adjusted operating income

92,010

88,711

176,168

171,943Amortization of intangibles

(15,379)

(18,559)

(30,729)

(38,300)Acquisition related expenses and other

(2,093)

(2,195)

(5,444)

(3,896)Certain litigation charges

(2,140)

(1,386)

(4,549)

(1,678)Stock-based compensation, inclusive of employer taxes

(14,198)

(15,238)

(26,294)

(25,875)Restructuring and restructuring-related costs

(3,739)

(3,287)

(11,249)

(14,309)Recovery of assets held-for-sale

—

—

6,789

—Impact of business held-for-sale(1)

—

(627)

(2,573)

(479)Operating income
$54,461
$47,419
$102,119
$87,406

(1)December 31, 2024 amounts relate to the Protein Sciences segment business that met the held-for-sale criteria on December 31, 2023. December 31, 2025 amounts relate to the Diagnostics and Spatial Biology segment business that met the held-for-sale criteria on June 30, 2025. BIO-TECHNE CORPORATIONCONDENSED CONSOLIDATED BALANCE SHEETS(In thousands)(Unaudited)



December 31,

June 30,

2025
2025ASSETS





Cash and equivalents
$172,879
$162,186Accounts receivable, net

184,614

206,876Inventories

205,447

189,446Current assets held-for-sale

—

12,332Other current assets

74,492

37,460Total current assets

637,432

608,300






Property and equipment, net

234,383

245,719Right of use assets

68,249

73,399Goodwill and intangible assets, net

1,315,551

1,346,534Other assets

267,084

283,916Total assets
$2,522,699
$2,557,868






LIABILITIES AND STOCKHOLDERS' EQUITY





Accounts payable and accrued expenses
$91,632
$116,765Contract liabilities

31,030

32,571Income taxes payable

2,476

10,770Operating lease liabilities - current

13,710

14,098Other current liabilities

1,578

1,645Total current liabilities

140,426

175,849






Deferred income taxes

11,021

6,169Long-term debt obligations

260,000

346,000Operating lease liabilities

77,185

83,960Other long-term liabilities

23,078

27,082Stockholders' equity

2,010,989

1,918,808Total liabilities and stockholders' equity
$2,522,699
$2,557,868 BIO-TECHNE CORPORATIONCONDENSED CONSOLIDATED CASH FLOWS(In thousands)(Unaudited) 

Six Months Ended

December 31, 

2025
2024CASH FLOWS FROM OPERATING ACTIVITIES





Net earnings
$76,194
$68,490Adjustments to reconcile net earnings to net cash provided by operating activities





Depreciation and amortization

49,049

55,221Costs recognized on sale of acquired inventory

—

373Deferred income taxes

5,203

(13,417)Stock-based compensation expense

25,640

24,892(Gain) Loss on equity method investment

(404)

(420)Asset impairment restructuring

3,253

9,841Recovery of assets held-for-sale

(6,789)

—Other operating activities

(42,150)

3,255Net cash provided by (used in) operating activities

109,996

148,235CASH FLOWS FROM INVESTING ACTIVITIES





Proceeds from sale of available-for-sale investments

—

1,085Additions to property and equipment

(11,284)

(15,993)Distributions from Wilson Wolf

1,351

1,403Investment in Spear Bio

—

(15,000)Proceeds from sale of assets held-for-sale

4,617

1,789Net cash provided by (used in) investing activities

(5,316)

(26,716)CASH FLOWS FROM FINANCING ACTIVITIES





Cash dividends

(24,914)

(25,424)Proceeds from stock option exercises

28,234

30,641Long-term debt activity, net

(86,000)

(19,000)Repurchases of common stock

(24)

(75,628)Taxes paid on RSUs and net share settlements

(10,486)

(5,997)Net cash provided by (used in) financing activities

(93,190)

(95,408)Effect of exchange rate changes on cash and cash equivalents

(797)

(353)Net increase (decrease) in cash and cash equivalents

10,693

25,758Cash and cash equivalents at beginning of period

162,186

151,791Cash and cash equivalents at end of period
$172,879
$177,549 Use of Non-GAAP Financial Measures:This press release contains financial measures that have not been calculated in accordance with accounting principles generally accepted in the U.S. (GAAP). We provide these measures as additional information regarding our operating results. We use these non-GAAP measures internally to evaluate our performance and in making financial and operational decisions, including with respect to incentive compensation. We believe that our presentation of these measures provides investors with greater transparency with respect to our results of operations and that these measures are useful for period-to-period comparison of results. Investors are encouraged to review the reconciliations of non-GAAP financial measures used in this press release to their most directly comparable GAAP financial measures as provided with the financial statements attached to this press release.Our non-GAAP financial measure of organic revenue and organic revenue growth represent revenue growth excluding revenue from acquisitions within the preceding 12 months, the impact of foreign currency, the impact of businesses held-for-sale, as well as the impact of partially-owned consolidated subsidiaries. Excluding these measures provides more useful period-to-period comparison of revenue results as it excludes the impact of foreign currency exchange rates, which can vary significantly from period to period, and revenue from acquisitions that would not be included in the comparable prior period. Revenues from businesses held-for-sale are excluded from our organic revenue calculation starting on the date they become held-for-sale as that revenue will not be comparable in future periods. Revenues from partially-owned subsidiaries consolidated in our financial statements are also excluded from our organic revenue calculations, as those revenues are not fully attributable to the Company. There was no revenue from partially-owned consolidated subsidiaries in fiscal years 2026 or 2025.Our non-GAAP financial measures for adjusted gross margin, adjusted operating margin, adjusted EBITDA, and adjusted net earnings, in total and on a per share basis, exclude stock-based compensation, which is inclusive of the employer portion of payroll taxes on those stock awards, the costs recognized upon the sale of acquired inventory, amortization of acquisition intangibles, and restructuring and restructuring-related costs. Stock-based compensation is excluded from adjusted net earnings because of the nature of this charge, specifically the varying available valuation methodologies, subjective assumptions, variety of award types, and unpredictability of amount and timing of employer related tax obligations. The Company excludes amortization of purchased intangible assets, purchase accounting adjustments, including costs recognized upon the sale of acquired inventory, and other non-recurring items including gains or losses on goodwill and long-lived asset impairment charges, and one-time assessments from this measure because they occur as a result of specific events, and are not reflective of our internal investments, the costs of developing, producing, supporting and selling our products, and the other ongoing costs to support our operating structure. Costs related to restructuring and restructuring-related activities, including reducing overhead and consolidating facilities, are excluded because we believe they are not indicative of our normal operating costs.  Additionally, these amounts can vary significantly from period to period based on current activity. The Company also excludes revenue and expense attributable to partially-owned consolidated subsidiaries as well as revenue and expense attributable to businesses held-for-sale in the calculation of our non-GAAP financial measures.The Company's non-GAAP adjusted operating margin, adjusted EBITDA, and adjusted net earnings, in total and on a per share basis, also exclude acquisition related expenses inclusive of the changes in fair value of contingent consideration, and other non-recurring items including certain costs related to the transition to a new CEO, goodwill and long-lived asset impairments, and gains. We also exclude certain litigation charges which are facts and circumstances specific including costs to resolve litigation and legal settlement (gains and losses). In some cases, these costs may be a result of litigation matters at acquired companies that were not probable, inestimable, or unresolved at the time of acquisition.The Company's non-GAAP adjusted EBITDA and adjusted net earnings, in total and on a per share basis, also excludes gains and losses from investments, as they are not part of our day-to-day operating decisions (excluding our equity method investment in Wilson Wolf as it is certain to be acquired in the future) and certain adjustments to income tax expense. Additionally, gains and losses from investments that are either isolated or cannot be expected to occur again with any predictability are excluded. The Company independently calculates a non-GAAP adjusted tax rate to be applied to the identified non-GAAP adjustments considering the impact of discrete items on these adjustments and the jurisdictional mix of the adjustments. In addition, the tax impact of other discrete and non-recurring charges which impact our reported GAAP tax rate are adjusted from net earnings. We believe these tax items can significantly affect the period-over-period assessment of operating results and not necessarily reflect costs and/or income associated with historical trends and future results.





View original content to download multimedia:https://www.prnewswire.com/news-releases/bio-techne-releases-second-quarter-fiscal-2026-results-302678364.htmlSOURCE Bio-Techne Corporation

Original: Bio-Techne Releases Second Quarter Fiscal 2026 Results

Bio-Techne Expands 3D Stem Cell and Organoid Culture Portfolio with a Fully Defined Synthetic AlternativeFebruary 2, 2026 6:30 AM
PR Newswire (US)

Fully defined, synthetic ECM designed to improve reproducibility and reduce lot-to-lot variabilitySupports standardization of scalable 3D stem cell and organoid workflowsSynthetic alternative to traditional matrices, enabling consistent performance while aligning with regulatory and translational initiativesMINNEAPOLIS, Feb. 2, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a global provider of life science tools, reagents and diagnostic products, today announced the launch of Cultrex™ Synthetic Hydrogel, a fully defined synthetic extracellular matrix (ECM) designed to support reproducible and scalable 3D stem cell and organoid research. The new product expands Bio-Techne's established Cultrex ECM portfolio, offering researchers a synthetic alternative that reduces lot-to-lot variability while supporting translational and regulatory-aligned research workflows alongside the Company's widely used traditional matrices.Cultrex Synthetic Hydrogel is designed to support the use of 3D organoid models across a wide range of applications, including drug screening, toxicology and personalized medicine, reducing the reliance on animal-component derived matrices and supporting the broader utilization of new approach methodologies (NAMs). By avoiding the biological variability inherent in traditional ECMs, the hydrogel helps researchers standardize experimental conditions across studies and laboratories, enabling more consistent and reliable organoid culture.Cultrex Synthetic Hydrogel aligns with the FDA's broader goal of driving innovation to improve translational outcomes by offering a more reliable platform for preclinical research. With the regulatory drive for increased adoption of NAMs across the pharmaceutical industry, researchers increasingly require tools that improve the scalability, consistency, and documentation surrounding organoid workflows. The Cultrex Synthetic Hydrogel launch represents an important step toward the broader adoption of organoid models in support of translational and regulatory-aligned research. Its controlled composition supports consistency and traceability as programs advance toward regulatory-facing studies."This product reflects the evolving needs of researchers as stem cell and organoid models move more quickly from discovery into translational workflows," said Will Geist, President of the Protein Sciences Segment at Bio-Techne. "Cultrex Synthetic Hydrogel expands our Cultrex ECM portfolio with a fully defined, scalable option that supports reproducibility and consistency as programs mature, without compromising the performance that researchers expect."This launch further expands Bio-Techne's robust portfolio of solutions for stem cell and organoid culture, including Cultrex Basement Membrane Extracts (BME), as well as recombinant cytokines and growth factors, AI-modified proteins, small molecules, media, and supplements. Together, these offerings provide researchers with the flexibility to select ECM solutions aligned with their experimental, scalability, and regulatory needs.Visit the website to learn more about Cultrex Synthetic Hydrogel.About Bio-Techne 
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With hundreds of thousands of products in its portfolio, Bio-Techne generated over $1.2 billion in net sales in fiscal 2025 and has approximately 3,100 employees worldwide. For more information, visit https://www.bio-techne.com or follow the Company on social media at LinkedIn, X and YouTube.MEDIA CONTACTS:Corporate Communications
media.relations@bio-techne.comDavid Clair, Vice President
Investor Relations
IR@bio-techne.com





View original content to download multimedia:https://www.prnewswire.com/news-releases/bio-techne-expands-3d-stem-cell-and-organoid-culture-portfolio-with-a-fully-defined-synthetic-alternative-302675775.htmlSOURCE Bio-Techne Corporation

Original: Bio-Techne Expands 3D Stem Cell and Organoid Culture Portfolio with a Fully Defined Synthetic Alternative

Bio-Techne Launches Simple Plex Ultra-Sensitive Assays on Ella Platform to Enable Femtogram-Level Detection of Neurological BiomarkersJanuary 28, 2026 11:30 AM
PR Newswire (US)

Detects low-abundance proteins in blood at femtogram concentrations for earlier disease insightsSupports research in Alzheimer's, ALS, MS, Parkinson's Disease, and Traumatic Brain Injury with validated biomarkersAutomated immunoassay workflow reduces variability; total runtime is under three hoursMINNEAPOLIS, Jan. 28, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a global provider of life science tools, reagents, and diagnostic products, today announced the launch of Simple Plex Ultra-Sensitive Assays on the Ella automated benchtop platform.Early detection of neurodegenerative disease biomarkers has historically been limited by their extremely low abundance in accessible biofluids such as blood. The new, ultrasensitive assays overcome this barrier by delivering step-change improvements on the Ella platform in analytical sensitivity and reliable quantification of key biomarkers, including NFL, GFAP, pTau 217, and Amyloid ß (aa1-42).This capability enables researchers to detect subtle, early biological changes that are often missed, accelerating insights into disease onset, progression, and treatment response. The assays build on Ella's proven performance, which is cited in more than 200 peer-reviewed neurology-focused publications and widely adopted in translational and clinical research, driving breakthrough diagnostic and therapeutic advances. "The introduction of Simple Plex Ultra-Sensitive assays on Ella significantly advances the analytical capabilities available for neurodegenerative disease research. By combining femtogram-level detection with a fully automated microfluidic platform, Ella enables precise quantification of low-abundance biomarkers that are often undetectable with conventional immunoassay methods," said Will Geist, President of Bio-Techne's Protein Sciences Segment. "This enhanced sensitivity and reproducibility support earlier characterization of disease-related changes and strengthen the reliability of high-throughput studies aimed at defining disease trajectories and?identifying?novel therapeutic targets."?? Ella's automated workflow reduces manual steps and variability, delivering ultrasensitive assay results with an overall runtime of under three hours. These assays are intended for Research Use Only.  This launch strengthens Bio-Techne's immunoassay leadership by combining ultrasensitive proteomic assays with automated instrumentation that improves reproducibility, throughput, and data quality. The Ella platform has been cited in more than 1,000 peer-reviewed publications. Bio-Techne's broad proteomic and spatial biology portfolio continues to drive breakthroughs in neuroscience research and advance precision medicine. For more information, visit www.bio-techne.com/ultrasensitiveAbout Bio-Techne  
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. With hundreds of thousands of products in its portfolio, Bio-Techne generated over $1.2 billion in net sales in fiscal 2025 and has approximately 3,100 employees worldwide. For more information on Bio-Techne and its brands, please visit www.biotechne.com and follow the Company on LinkedIn, YouTube, and XMedia Contacts? 
Corporate Communications?? 
media.relations@biotechne.com David Clair  
Vice President, Investor Relations & Corporate Development 
david.clair@biotechne.com 





View original content to download multimedia:https://www.prnewswire.com/news-releases/bio-techne-launches-simple-plex-ultra-sensitive-assays-on-ella-platform-to-enable-femtogram-level-detection-of-neurological-biomarkers-302672022.htmlSOURCE Bio-Techne Corporation

Original: Bio-Techne Launches Simple Plex Ultra-Sensitive Assays on Ella Platform to Enable Femtogram-Level Detection of Neurological Biomarkers

UK SMEs Are Rapidly Adopting Digital Transformation — Interesting Report

I came across a recent article analysing how UK small and medium-sized businesses are adapting to digital transformation — covering automation, data use, and tech investment trends.

It’s a short but insightful read for anyone interested in how smaller firms are using digital tools to stay competitive:
👉 https://rdmarketing.co.uk/knowledge-hub/how-uk-smes-are-adopting-digital-transformation/

Curious what others here think — are SMEs keeping pace with larger companies on digital adoption, or is there still a major gap?

TECH under $75

TECH range bound

TECH under $100

Top Meme Stock Mentions Money to Move 01/03/2022

$TECH: $2B

Money to Move is a proprietary estimate of the total added monetary volume required to move a stock based on float liquidity and short percentage. Updated daily for high social interest stocks.

See more... https://gravityanalyticaresearch.com https://gravityanalytica.com

Top Meme Stock Mentions Money to Move 10/15/2021

$TECH: $2B

Money to Move is a proprietary estimate of the total added monetary volume required to move a stock based on float liquidity and short percentage. Updated daily for high social interest stocks.

See more... https://gravityanalyticaresearch.com https://gravityanalytica.com

Top Meme Stock Mentions Money to Move 10/14/2021

$TECH: $1B

Money to Move is a proprietary estimate of the total added monetary volume required to move a stock based on float liquidity and short percentage. Updated daily for high social interest stocks.

See more... https://gravityanalyticaresearch.com https://gravityanalytica.com

NO REASON.

No worries, just read a blurb on a new diet drug that sounds pretty promising from these guys. Fexaramine, from these guys, looking at clinicals in 2-3 years.

Is there a reason you're no longer following it or just got tired and needed more time with others?

NO longer follow TECH.
SORRY

Hey Trend, saw you over on AAL. This guy just popped up on my radar, obviously nothing going on in the board. What are your thoughts on this, if you have any beyond your charts? Not sure if you're on this one or not.

TECH D